Federal Oversight and Strategic Choices of Kidney Transplant Centers *

Han Ng [†]

this version: April 2025

Click here for the latest draft.

Abstract

Kidney transplant centers significantly influence patient survival, yet regulatory oversight of their performance and practices remains limited. This study evaluates a policy designed to terminate centers whose post-transplant mortality exceeds risk-adjusted thresholds. Using variation in policy exposure across centers and novel follow-up data, I employ a difference-in-difference approach to estimate the policy's impact on patient outcomes and center behaviors. The policy reduced post-transplant mortality by 20 - 25%, though the mechanisms driving the improvements evolved over time. Initially, centers responded by performing fewer transplants after the policy announcement, thereby avoiding high-risk kidney matches. Over time, transplant volume recovered as centers adapted, increasing immunosuppressant prescriptions to prevent kidney rejection and enhancing viral testing protocols to manage associated side effects. These findings suggest that centers initially reduced transplants due to unfamiliarity regarding policy nuances but subsequently shifted toward actively improving post-transplant care.

JEL codes: I11, I18, L38

Keywords: quality regulation, kidney transplant, mortality rates, Medicare

1   Introduction

Transplant centers are crucial in helping the 100,000 patients on the national waitlist obtain a kidney transplant and recover from kidney failure. Despite receiving significant reimbursements from the Centers for Medicaid and Medicare Services (CMS)[1], there was limited oversight of center behavior and performance until high-profile issues, such as poor patient outcomes and inefficiencies, came to light in 2005[2]. These concerns prompted the announcement of a federal oversight program (GAO, 2008). The program enabled CMS to evaluate and guide transplant centers in identifying areas for quality improvement and enhancing the efficiency of care delivery. However, the accompanying financial penalties for poor performance can introduce unintended incentives. For instance, to avoid penalties, centers may cherry-pick patients by prioritizing those with lower-risk profiles, potentially leading to kidney wastage and denying transplants to patients who might benefit the most (Sack, 2012).

This paper examines the effects of federal oversight on post-transplant mortality and treatment decisions. I leverage exogenous variation in penalty exposure created by one of the most extensive oversight programs in the US deceased donor kidney transplant system. Specifically, I study CMS's Conditions of Participation (CoP) policy, announced in February 2005 and implemented in July 2007. The policy penalizes transplant centers for having risk-adjusted post-transplant mortality rates exceeding specified limits. Post-transplant mortality, defined as death or graft failure within 365 days after the transplant, carries significant consequences under the CoP, as centers can lose certification if flagged more than twice over 30 months (Federal Register, 2007). Given CMS's status as the largest purchaser of organ transplantation services, the threat of withdrawal commands immediate attention from center leadership (Hamilton, 2013).

Centers could respond to the threat of punishment in two ways. First, as policymakers intended, centers could improve post-transplant care. For example, acute kidney rejection, the most common post-transplant complication (Gjertson et al., 2002), can be mitigated by intensifying im-

---

[1]CMS spent 36 billion USD in 2017 on the care of renal failure patients, with approximately 13% allocated to kidney transplants (Sawani, 2019).
[2]Source: Kaiser puts kidney patients at risk.

munosuppressive regimens and dedicating more resources to monitoring and managing side effects. Secondly, centers may engage in selective behaviors, altering patient or kidney composition to reduce mortality rates. The Organ Procurement and Transplantation Network (OPTN) informs the center of biologically compatible kidneys, but administrators retain discretion over accepting or declining the kidney offers. The CoP's penalties may influence decisions for marginal patient-kidney pairs, as noted by a director in a 2012 *New York Times* article: "... *if you have had a couple of bad outcomes recently you say, 'Well, why should I do this?'... You can always find a reason to turn organs down...*"[3]. These potential trade-offs make oversight policies particularly controversial in kidney transplantation. To address these concerns, I investigate how much of the observed decline in mortality reflects improvements in post-transplant care versus the impact of selection mechanisms.

To motivate the empirical analysis, I consider a stylized model of center behavior to understand how federal oversight affects transplant decisions and post-transplant care. The center observes a noisy signal of patient health and decides whether to select the patient for transplant. Then, it provides post-transplant care. These decisions jointly determine the center's post-transplant mortality. CMS reimburses the center if mortality falls below a specified limit. The center aims to maximize profit by performing as many transplants as possible and providing comprehensive post-transplant care. However, it also faces tradeoffs: performing too many transplants increases the risk of exceeding mortality limits and incurring penalties, while excessive post-transplant care is costly for patients[4]. The model illustrates how the center optimizes these competing objectives. Under the CoP policy, the return to marginal transplants is reduced due to heightened performance scrutiny, while the return to improved post-transplant care increases, incentivizing a shift in behavior.

The primary data sources are administrative follow-up records for all transplant patients, comprehensive patient-kidney offers data, and CMS's CoP report. The dataset spans from 2001 to 2012, covering approximately four years before, two years after the 2005 CoP announcement, and five years after the 2007 implementation. The follow-up data tracks each transplant patient's health

---

[3]Source: New York Times

[4]For example, patients' coinsurance kicks in or increases the opportunity cost of the patient's time.

status and records all prescriptions and medical tests performed during the revisits. The patient-kidney offer dataset records all kidney offers, including information on the final decision, offer dates, reasons for declining, and detailed patient and kidney characteristics. The CoP report documents the center's flagging status, highlighting key center-level characteristics and offering critical insights into how centers were evaluated under the CoP.

The research design exploits two sources of policy-driven variation. First, the announcement and delayed implementation affect centers differentially, creating cross-sectional variation in penalty beliefs. Second, the announcement introduces within-center temporal variation. Centers are not randomly assigned to the penalty, and the panel is crucial in eliminating constant unobserved differences across centers. This setting, therefore, lends itself to a difference-in-differences research design. I follow Gupta (2021) and construct a continuously varying measure of center expectations of exceeding the CoP threshold in the program's first year based on their past mortality and transplant volume. This approach leverages the fact that mortality rates are persistent over time, and hence, past performance is a valuable predictor of future flagging likelihood. This measure incorporates the intensive margin of the penalty incentive, i.e., centers with excellent recent performance are expected to have a lower likelihood of being flagged.

However, estimates obtained via ordinary least squares (OLS) using this measure could be biased upwards due to mean reversion (Chay, McEwan and Urquiola, 2005; Gupta, 2021). I circumvent this problem using an instrumental variable (IV) approach, thereby mitigating concerns about measurement error. The instrument is a predicted mortality rate based on patient-kidney factors estimated using transplant samples from 2002 to 2004. All else equal, centers with a higher proportion of these patients were more likely to be penalized. The identifying assumption is that in the absence of CoP, centers with high versus low predicted mortality, held constant as in 2005, would evolve along parallel trends. To explore the validity of this assumption, I present nonparametric estimates of dynamic effects on all key outcomes.

The baseline IV estimates imply that after Medicare announced CoP, a one-standard-deviation increase in center belief resulted in a 2.78 percentage point (pp) (25%) decrease in post-transplant

1-year mortality. The pattern persisted even after Medicare implemented CoP. OLS estimates are substantially smaller, consistent with downward bias due to mean reversion. This estimate will understate the aggregate effects of the penalty.

Applying the same research design, I examine how selection and improved post-transplant care influenced mortality across different policy phases. Initially, detailed patient-kidney offer data reveal that after CMS announced CoP, centers became 7% less likely to transplant a given patient-kidney pair. This cautious approach led to more high-risk kidneys being discarded, inadvertently reducing mortality due to fewer risky transplants. However, this selective behavior dissipated as Medicare implemented CoP. Using follow-up data, I quantify subsequent improvements in post-transplant care during the implementation period. Immunosuppressant prescriptions increased by 8% during follow-up visits, complemented by expanded viral infection testing, which coincided with lower infection-related mortality, a key side-effect of heightened immunosuppressive regimens. These findings suggest initial policy uncertainty triggered cautious selection, but over time, centers adapted by restoring transplant volumes and significantly improving clinical practices.

Several patterns suggest a causal interpretation of these results. First, there are no differential pretrends across centers at different levels of penalty risk. Second, the timing of the changes coincides with the announcement of the CoP policy. Third, I find statistically insignificant effects on otherwise similar outcomes that were not incentivized by the program, such as post-transplant mortality rates beyond the first year. Fifth, the estimates are robust to various specification checks.

1.1 Related literature

This paper contributes to three main strands of literature. First, it engages with the economic debate on centralized quality disclosure [5]. Closely related studies, such as Dranove et al. (2003); Jin and Sorensen (2006); Bundorf et al. (2009); Ramanarayanan and Snyder (2012); Feng Lu (2012); Kolstad (2013); Gupta (2021); Vatter (2023), examine provider responses to such policies in health-

---

[5]Dranove and Jin (2010) reviews the theoretical and empirical literature on quality disclosure. Their paper highlights various healthcare, finance, and education examples.

care contexts, including coronary artery bypass grafts, fertility clinics, nursing homes, hospital readmissions, and health plan ratings. My paper adds to existing work by identifying a transitory adjustment period during which uncertainty or adaptive behavior led to unintended short-term resource wastage. This finding highlights how government agencies can facilitate organizational learning and minimize unintended consequences during policy transition.

Second, this paper contributes to economic research on deceased donor organ transplants, which predominantly examines the design of allocation systems (Su and Zenios, 2005; Zhang, 2010; Bloch and Cantala, 2017; Agarwal, Hodgson and Somaini, 2020; Agarwal et al., 2021; Leshno, 2022; Doval et al., 2024; Sweat, 2024). In contrast, I analyze how federal oversight influences the behavior of transplant centers, offering an alternative perspective on how policy shapes outcomes through post-transplant care. Related work, such as Bae (2024) and Dickert-Conlin, Elder and Teltser (2019), investigates external factors, including donor service area boundary redrawing and state-level policies affecting allocation and mortality. My analysis shifts the focus to center-level behavioral responses, providing insights into the direct impact of regulatory oversight.

Third, this paper contributes to the literature on the causal effects of CoP by addressing limitations in previous studies that rely on cross-sectional variation in center flagging status (Schold, Arrington and Levine, 2010; Schold et al., 2013; Hamilton, 2013) or within-center temporal variation (White et al., 2014). Closely related is Stith and Hirth (2016), which employs a difference-in-differences design but focuses on centers transitioning in and out of treatment status, complicating causal interpretation. My paper contributes to existing work by utilizing novel follow-up data to highlight the impact of CoP on post-transplant care practices. Moreover, the 2.5-year gap between CoP's announcement and implementation provides a unique opportunity to mitigate concerns about changing treatment status and anticipatory behavior, strengthening the credibility of causal inferences.

1.2 Roadmap

I organize the rest of the paper as follows. Section 2 describes the institutional details and the

CoP policy. Section 3 describes the model. Section 4 describes the data. Section 5 describes the research design. Section 6 presents results on mortality and the various mechanisms at different CoP phases. Section 7 presents robustness checks of the main results. Section 8 concludes.

2 Institutional background

A patient diagnosed with end-stage renal disease (ESRD) has two options: dialysis or kidney transplant[6]. Dialysis requires two to three treatments a week. Sessions are time-consuming; patients can be infected if nurses do not disinfect stations appropriately after use. These disadvantages make kidney transplants the cheaper alternative (Matas and Schnitzler, 2004). In this paper, I focus exclusively on deceased donor kidney transplant that accounts for 60% of all kidney transplants in the U.S. (AKF, 2003)[7]. This section describes how patients get on the waitlist, how the centralized system allocates kidneys, what post-transplant follow-up care is, and the details of the Conditions of Participation (CoP).

2.1 Getting on the waitlist

The physician refers patients to a local transplant center when they have kidney failure[8]. The center's selection committee will evaluate if the patient is eligible for a kidney transplant (i.e., started dialysis or had a glomerular filtration rate (GFR) below 20mL per minute). The center will then register accepted patients on the national deceased donor waitlist and upload important information such as immunological profile, health conditions, and factors to compute into the UNet system (AKF, 2003).

---

[6]Dialysis is a treatment that removes waste and excess water from the blood. There are two types of dialysis: hemodialysis and peritoneal dialysis.

[7]Kidney exchange is an alternative way of getting a kidney transplant (Roth, Sonmez and Unver, 2004). However, patients need a willing living donor, which can sometimes be logistically cumbersome. Hence, kidney exchange is considered a different program to a deceased donor kidney transplant.

[8]Patients usually follow the physician's recommendation because the local transplant center is logistically convenient and does not disrupt their dialysis routine (Schaffhausen et al., 2019). The average distance between a patient's home and the nearest center is 23 miles (Purnell and McAdams-DeMarco, 2020).

2.2 Kidney allocation and transplant process

The Organ Procurement and Transplantation Network (OPTN) designs and administers the centralized deceased donor kidney allocation process. Centers upload a deceased donor's medical history and organ condition into UNet when brain or cardiac death is imminent. The system identifies biologically compatible patients and ranks them according to their priority order. Many factors contribute to the order, including, but not limited to, blood type, duration on the waitlist, where the patient lives, and, in some instances, weight and size compared to the donor.

Recovered kidneys become unsuitable for transplants after 24-36 hours. So, UNet simultaneously contacts multiple transplant centers about their compatible patients to speed up the matching process. When contacted, a transplant center has 1 hour to decide which patient receives the kidney offer. During this hour, surgeons receive information about the donor's medical history and can request additional information from the donor's hospital. At the same time, surgeons also evaluate their patient's health condition and decide if the patient is available or suitable for the transplant. For example, the patient's condition might have deteriorated since the last evaluation, or the patient might be unavailable due to a family emergency. The transplant center does not contact every compatible patient because of the tight deadline[9]. It usually informs the patient after UNet confirms the center's acceptance (King et al., 2023; Husain et al., 2025)

If UNet receives multiple acceptances, the center with the highest-priority patient will receive the kidney. After receiving the kidney, the center conducts a final blood test using samples from both the patient and the donor. [10]. Otherwise, the center declines the kidney offer, and UNet contacts the next center. UNet removes the patient from the waitlist 24 hours after a successful transplant. In the case of a declined kidney offer, the patient returns to the waitlist without any penalty on their priority for the next kidney offer (OPTN, 2023).

There are two channels through which the center affects the type of kidney that its patients are matched with. First, the center can set acceptable donor criteria for each patient on UNet. For

---

[9]Furthermore, no regulations mandate transplant centers to notify patients of their kidney offers (OPTN, 2023).

[10]This blood test is called a serum crossmatch. It mixes the donor cells with the patient's blood to determine if the antibodies will bind to the donor cells and cause kidney damage. Source: Blood tests for transplant

example, the center can limit the patient's maximum donor age to 80. As a result, kidneys from donors over the age of 80 will not be offered to the patient, even if they are biologically compatible. Second, due to the tight one-hour deadline, the center usually accepts or declines incoming kidney offers on the patient's behalf. I leverage the patient's acceptable donor criteria and patient-kidney offer data to examine how CoP affects these two channels.

2.3   Post-transplant care and acute kidney rejection

Centers typically discharge patients within 8 to 14 days post-transplant. After discharge, patients will visit the center for regular check-ups at defined intervals (e.g., 6 months, 1 year, 2 years, etc.) to monitor their recovery and kidney function.

Acute kidney rejection, an immune response typically occurring within the first 12 months post-transplant, is the most common post-transplant complication [11]. During rejection episodes, the patient's immune system, particularly T-cells and antibodies, attacks the foreign kidney, potentially leading to impairment and graft failure (Becker et al., 2022). To mitigate this, centers prescribe immunosuppressant medications during the recovery period. However, immunosuppressants compromise patients' immune systems, increasing vulnerability to viral infections. Cytomegalovirus (CMV) is an example of a viral infection that is particularly prevalent in transplant patients who receive immunosuppressant therapy[12]. CMV infection often presents asymptomatically, though patients may occasionally experience symptoms such as fever, localized pain at the transplant site, or reduced urine output. Therefore, early detection through follow-up sessions significantly enhances graft survival and kidney function preservation (López-Oliva et al., 2017; Al Atbee and Tuama, 2022).

In Section 6.3, I leverage follow-up data that track patient health status, immunosuppressant prescriptions, and outcomes from diagnostic tests to analyze the impact of CoP on centers' post-transplant care practices for preventing acute kidney rejection and detecting viral infections from

---

[11]Approximately $15\% - 20\%$ of transplanted patients will experience some degree of kidney rejection. Source: Cleveland Clinic.

[12]Source: Cedars Sinai

immunosuppressant therapy.

2.4   Conditions of Participation (CoP)

Before July 2007, OPTN was the primary organization responsible for monitoring a transplant center's number of post-transplant survival but only twice recommended to the Department of Health and Human Services to remove a transplant center's certification (GAO, 2008). Following several high-profile problems that came into light in 2005, CMS became concerned that the lack of severe penalties for poor performance may have led to a decline in the quality of kidney transplants[13]. As stated in the Final Rule establishing the increase in CMS oversight:

> " The OPTN generally takes a collegial approach and assists the center in improving
> their performance, while we generally take a regulatory approach which sometimes
> may lead to termination ..." (Federal Register, 2007)

CMS announced CoP in February 2005 and implemented it in July 2007. The policy provides a foundation for improving quality and protecting the health and safety of transplant centers (Federal Register, 2005). Centers submit the 1-year post-transplant outcomes of a rolling 2.5-year cohort to the Scientific Registry of Transplant Recipients (SRTR) in the first week of every January and July. Figure C.III illustrates an example of a rolling 2.5-year cohort. The January 2011 submission (black box) consists of transplants from July 1, 2007, to December 31, 2009 (black line). Similarly, the July 2011 submission (red box) includes transplants from January 1, 2008, to June 30, 2010 (red line). CMS flags a transplant center for poor performance if all of the following criteria are satisfied:

1. $O/E \geq 1.5$

2. $O - E \geq 3$

3. $Pr(O = E) \leq 0.05$

---

[13]Source: Los Angeles Times

O is the center's observed number of patient deaths or graft failures within 1 year post-transplant; E is the center's expected number of patient deaths or graft failures within 1 year post-transplant. SRTR calculates E by estimating a Cox regression model (Cox, 1972), using all the transplants in the rolling 2.5-year cohorts submitted by each transplant center. The model utilizes extensive patient, donor, and match characteristics, including, but not limited to, age, race, diabetic status, donor cause of death, and human leukocyte antigen (HLA) matching. However, the model does not include center characteristics because *"center characteristics and practices may be associated with the differences we are trying to identify and therefore should not be risk-adjusted away."* (Dickinson et al., 2008). Criterion one states that the center's observed deaths have to exceed expected deaths by 50%. Criterion two states that the difference between the observed and expected deaths must be greater than 3. Finally, criterion three states that if observed deaths are different from expected deaths, the difference has to be statistically significant at 95% significance level. Intuitively, criteria one and two state that the center cannot have too many observed deaths; criteria three can be interpreted as CMS's attempt to protect low-volume transplant centers from statistical anomalies in patient deaths. For example, a patient death is more likely to push a low-volume center's OE death ratio in criteria one above the 1.5 limit compared to a high-volume center (Federal Register, 2005)[14].

Once CMS flags a center for poor performance, it implements a data-driven quality assessment and performance improvement (QAPI) system. If CMS flags the center again within the next 30 months, it risks losing its program certification and Medicare funding. However, most centers have 210 days to appeal that their poor performance is due to mitigating circumstances. I present an example of a CoP report in Figure C.IV.

---

[14]I account for transplant volume and unadjusted mortality in Section 5.1 when constructing center flagging beliefs.

	Stage 1		Stage 2		Stage 3

Observe: signal, $\tilde{x}$ **Observe:** health, x **Observe:** death rate,
Choice: accept/decline,   **Choice:** post-transplant $P(x, q(x))$ and receive
$A(\tilde{x})$ care, $q(x)$ payments

Figure I: Timeline of the center behavior

3 Conceptual framework

In this section, I formalize the transplant center's incentives and explore how CoP affects decision-making. I present a stylized model where the center observes a noisy signal of patient health and then chooses the transplant eligibility threshold and the amount of post-transplant care. The center must balance the tradeoffs between profit, patient welfare, and CoP compliance. Specifically, it weighs the revenue from transplant procedures and post-transplant care against regulatory penalties associated with high patient mortality. The model delivers two predictions about the center's response to CoP implementation. First, CoP raises the marginal cost of each transplant by increasing the penalty for poor outcomes, leading centers to reduce transplants. Second, by penalizing poor outcomes, CoP incentivizes centers to improve post-transplant care despite the associated costs. In subsequent analysis, I model patient mortality in my setting, describe the center's objective function, and characterize the optimal transplant decision and post-transplant care. Finally, I provide comparative statics on key parameters and present proofs in Appendix A. Figure I illustrates the center's timeline and decision-making[15].

---

[15] For brevity, I abstract from the kidney decision in my current model. In Appendix B, I include an additional stage where the center chooses either a good or bad kidney. Both models have similar results on transplant threshold and post-transplant care.

3.1 Setup

Patient health is denoted as x, where $x \sim N(\mu_x, \sigma_x^2)$ [16]. However, when deciding whether to transplant, centers only observe a noisy signal of patient health, $\tilde{x} = x + u$, where $u \sim N(0, \sigma_u^2)$ is independent of x. Thus, $\tilde{x}$ is an unbiased signal for patient health x. After the transplant, centers observe x and decide on post-transplant care $q(x)$. Transplant patients die if the latent variable $y > 0$, where $y = \varepsilon - x - q(x)$ and $\varepsilon \sim N(0, \sigma^2)$ is a normally distributed idiosyncratic shock. Let the probability that a patient with health x and post-transplant care $q(x)$ die to be $P(x, q(x)) = 1 - \Phi\left(\frac{q(x)+x}{\sigma}\right)$, which is decreasing in q and x: more post-transplant care or healthier patient reduces the likelihood of transplant deaths. Conditional on transplant decision and post-transplant care, the center expects $\int_{\tilde{x}} A(\tilde{x}) \int_x P(x, q(x)) p(x|\tilde{x}) dx dF(\tilde{x})$ patients to die, where $p(x|\tilde{x})$ is the posterior distribution of x given $\tilde{x}$ and can be derived with Bayes' rule.

I follow Clemens and Gottlieb (2014); Dickstein (2017); Alexander (2020); Shi (2023) and model the center's objective function as a weighted combination of profit and concern for patient utility. The weight placed on profit is ρ and can be interpreted as the center's belief in punishment. In my setting, the center becomes more altruistic and places more weight on patient utility when the likelihood of punishment is low (i.e., low ρ). Medicare pays the center a fixed reimbursement π for each transplant and a reimbursement rate α for each unit of post-transplant care, $q(x)$. Thus, the center profit is $\pi + \alpha q(x)$. A center's concern for patient welfare can be understood as altruism on behalf of the patient or as the center acting to preserve its reputation (Alexander, 2020).

The patient's utility from post-transplant care is concave in $q(x)$, reflecting diminishing returns to care. Healthier patients (higher x) derive greater benefits from transplants, but excessive care imposes costs due to coinsurance or opportunity cost on patient's time (Senanayake et al., 2020). The patient receives zero if centers do not perform a transplant. The center maximizes utility and chooses $A(\tilde{x}), q(x)$ to maximize a weighted average of their profit and the patient's utility from transplant[17]:

---

[16]Patients with higher x are deemed healthier and more suitable for transplant (OPTN, 2023).

[17]The notation $q(x)$ indicates that centers observe patient health status when choosing post-transplant care.

$$\max_{A(\tilde{x}),q(x)} \int_{\tilde{x}} A(\tilde{x}) \int_x \left[\rho \overbrace{[\pi + \alpha q(x)]}^{\text{center profit}} + (1-\rho) \overbrace{\left[xq(x) - \frac{\gamma}{2}q^2(x) \right]}^{\text{patient utility}} \right] p(x|\tilde{x})dx \quad dF(\tilde{x})$$

(1)

$$\text{s.t.} \quad \overbrace{\int_{\tilde{x}} A(\tilde{x})}^{\text{small center discount}} \overbrace{\int_x P(x, q(x))p(x|\tilde{x})dx \, dF(\tilde{x})}^{\text{"not too many deaths"}} \leq \tau$$

τ is the CoP limit, and the rest of the terms in the constraint reflect the CoP conditions in Section 2.4. $\int_x P(x, q(x))p(x|\tilde{x})dx$ mimics conditions 1 and 2: there cannot be too many post-transplant deaths. However, even if it does, the center is exempted if condition 3 fails (i.e., the sample size is so small that differences between observed and expected deaths are statistically insignificant). $\int_{\tilde{x}} A(\tilde{x})dF(\tilde{x})$ mimics condition 3 and serves as a scaling factor that makes it less likely for small centers to exceed the CoP limit, τ.

Intuitively, the center balances competing incentives. On one hand, it seeks to maximize profit by performing more transplants and providing reimbursable care. On the other hand, performance concerns and patient welfare impose constraints: (i) transplanting too many patients increases the likelihood of exceeding the CoP mortality limit; (ii) patients dislike excessive post-transplant care due to the marginal cost $\gamma > 0$. The center optimally trades off these incentives by adjusting the transplant decision $A(\tilde{x})$ and post-transplant care $q(x)$. Next, I characterize the optimal $A^*(\tilde{x}), q^*(x)$ and present the proofs in Appendix A.

Proposition 1. *The optimal $q^*(x)$ is an implicit solution to the equation 10. $A^*(\tilde{x})$ takes the form of a cutoff strategy as defined in 11, and t^* is the transplant threshold where patients with $\tilde{x} \geq t^*$ will receive transplants and post-transplant care. Conversely, patients with $\tilde{x} < t^*$ will receive no transplants nor post-transplant care.*

3.2 Comparative statics

In this stylized model, the pre-CoP announcement reflects $\tau \to \infty$, meaning no effective regulatory constraints on the product of transplants and mortality, allowing centers to optimize without restrictions. The post-CoP announcement reflects $\tau < \infty$, introducing binding regulatory constraints. The following result illustrates the comparative statics for the transplant threshold t^* and post-transplant care $q^*(x)$ as CMS announces CoP (i.e., τ decreases). I present the proofs in Appendix A.

Proposition 2. *As CMS announces CoP (i.e., τ decreases), the transplant threshold t^* increases $\left(\frac{\partial t^*}{\partial \tau} < 0\right)$; post-transplant care $q^*(x)$ increases $\left(\frac{\partial q^*(x)}{\partial \tau} < 0\right)$.*

Proposition 2 predicts that the CoP announcement decreases the fraction of patients receiving transplants. This reduction is not necessarily due to centers selecting healthier patients, but rather a higher threshold t^* increases the likelihood that patients with better true health x surpass it. Consequently, the average health of transplanted patients rises (i.e., $\mathbb{E}[x|\tilde{x} \geq t^*]$ increases with t^*). The magnitude of this increase depends on how well the noisy signal $\tilde{x}$ reflects x. When $\tilde{x}$ is highly informative (low $\text{Var}(u)$), the stricter threshold effectively excludes less-healthy patients, substantially improving the average health of transplanted patients. Conversely, when $\tilde{x}$ is weakly informative (high $\text{Var}(u)$), the threshold has little effect on health composition.

The monotonic relationship between $\mathbb{E}[x|\tilde{x} > t^*]$ and t^* offers a way to evaluate the informativeness of unobserved $\tilde{x}$. If $\mathbb{E}[x|\tilde{x} > t^*]$ does not increase with t, it suggests that $\tilde{x}$ is dominated by noise (i.e., high $\text{Var}(u)$) and contains little information about x. Consequently, selection based on unobserved $\tilde{x}$ weakly correlates with x, reducing concerns about selection on unobservables threatening identification.

4 Data and descriptive analysis

This paper uses two administrative datasets from the OPTN: the Standard Transplant Analysis Research (STAR) and Potential Transplant Recipient (PTR) data. The OPTN data system includes data on all donors, waitlisted candidates, and transplant recipients in the U.S. submitted by its members.

4.1 Sample construction

The STAR dataset provides detailed information on patient and donor characteristics, as well as survival outcomes. Crucially, patients who receive a transplant are also included in follow-up data that tracks their health over time and records the medical tests performed during subsequent visits. The PTR dataset comprises all kidney offers generated by the system, along with records of accept or decline decisions. These datasets are populated using information gathered during the allocation process, forms submitted by transplant centers from patient follow-ups after a transplant, and patient death dates merged from social security records.

I restrict attention to patients who received a transplant between January 1st, 2001, and December 31st, 2012, which approximately spans 4 years before and 8 years after the CoP announcement in February 2005. From this set, I exclude patients who required multiple organ transplants, those who received a kidney from a living donor, and patients from pediatric transplant centers. Correspondingly, I only use data on donor offers and acceptance decisions for my sample of patients. This paper uses three different units of analysis. Section 6 uses patient-appointment information to analyze post-transplant mortality and post-transplant care. Section 6.2 uses patient-kidney offers to analyze transplant center accept-decline decisions. Section **??** uses kidney-level information to analyze kidney utilization.

4.2 Descriptive analysis

Figure II presents a time-series plot of the post-transplant 1-year mortality rate from 2001 to 2012, showing a steady decline from approximately 12% in 2001 to 6% in 2012. This reflects significant improvements in post-transplant survival over time. The downward trend appears to have accelerated after the CoP announcement in February 2005, suggesting that the CoP announcement may have contributed to these further improvements. For subsequent analysis, the period before February 2005 is considered the pre-CoP period, February 2005 to July 2007 is the post-CoP announcement period, and the period after July 2007 is the post-CoP implementation period. This timeline provides a natural framework for evaluating the impact of CoP on transplant outcomes.

Figure II: Post-transplant mortality decreasing from 2001-2012 (main analysis period)

Note: CMS announced CoP in February 2005, represented by the first red-dotted vertical line. CMS implemented CoP in July 2007, represented by the second red-dotted vertical line. I define the pre-CoP period as the time from January 2001 to February 2005, the post-CoP announcement period as February 2005 to July 2007, and the post-CoP implementation period as July 2007 to December 2012.

Table I presents summary statistics for the sample, with each row representing different follow-up intervals, while panels group key variables. Between 2001 and 2012, 124,600 patients received a deceased donor kidney transplant, with a 29-26-45 percent split across the three periods. Panel A shows that most transplanted patients attend follow-up appointments, demonstrating high compli-

17

ance rates. However, attendance declines over time due to post-transplant deaths, which account for 94 percent of non-compliance cases (Table D.I). Panel B indicates that kidney rejection rates at various follow-up intervals have remained stable across all three CoP periods. Panels C and D highlight a post-CoP increase in the prescription of maintenance immunosuppressive drugs and CMV testing at different follow-up intervals. Overall, the patterns in Table I highlight high patient compliance and provide preliminary evidence of evolving center practices aimed at improving the prevention and detection of acute kidney rejection. These trends are further examined in Section 6.3.

Table I: Follow-up outcomes before, after CoP announcement and implementation

Outcome Measure	Pre-CoP	Post-Announce	Post-Implement
Panel A: follow-up compliance			
2 weeks	98.4%	98.5%	98.8%
6 month	91.6%	92.6%	94.2%
1 year	87.8%	89.1%	91.4%
Panel B: kidney rejection rates			
2 weeks	3.0%	4.3%	2.3%
6 months	6.6%	6.3%	6.4%
1 year	3.9%	3.5%	3.6%
Panel C: prescription rates (prevent)			
2 weeks	97.6%	96.7%	97.4%
6 months	28.8%	85.6%	77.0%
1 year	38.5%	87.5%	89.9%
Panel D: CMV testing rates (detect)			
2 weeks	92.2%	94.6%	98.9%
1 year	6.8%	25.8%	38.5%
2 years	4.1%	35.4%	36.8%
Number of Observations	36446	27052	61106

Notes: This table presents summary statistics for follow-up outcomes before CoP, after CoP announcement, and implementation at different follow-up intervals. Panel A shows the percentage of patients who attended follow-up appointments. 94% non-compliers are due to deaths. Panels B, C, and D are conditional on patients attending follow-up appointments. Panel B shows the kidney rejection rates during follow-up. Panel C shows the likelihood of maintenance drug prescription during follow-up. Panel D shows CMV testing rates during follow-up.

Tables D.II and D.III compare transplant kidney and patient characteristics pre-CoP, post-CoP

18

announcements, and implementation. A comparison of columns in both tables reveals no significant differences in overall transplant profiles. However, Table D.III highlights a notable spike in dialysis patients receiving kidney transplants post-CoP. This trend is likely unrelated to centers favoring dialysis patients but instead reflects the broader expansion and consolidation of the two major dialysis chains, Davita and Fresenius, during this time, which increased the number of patients undergoing dialysis treatment (Eliason et al., 2019). Overall, these comparisons provide strong preliminary evidence that, while the total number of transplants has decreased, there is no clear indication that centers are selecting against specific transplant profiles. These patterns are further examined in Section 6.2.

5 Research design

The announcement of CoP in February 2005 created both cross-sectional variations in the marginal penalty incentives across centers and within-center temporal variation. This setting lends itself naturally to a differences-in-differences (DiD) research design to quantify the causal effect of the CoP announcement[18]. However, there are three empirical challenges to identifying these effects that the proposed design addresses.

First, CoP flags centers based on past mortality performance and suitable statistical adjustments. Since flagged and non-flagged centers differ in observable characteristics, relying solely on cross-sectional comparisons could introduce bias. To address this, I rely on within-center estimates to control for any time-invariant factors affecting center behavior.

Second, treatment status is not clearly defined because forward-looking center administrators strategize based on their expectations of exceeding CoP limits rather than waiting for the flagging status to be revealed. Simply comparing flagged and non-flagged centers may underestimate the center's response. Instead, I follow Gupta (2021) and model center behavior based on their expectations of exceeding CoP limits, conditional on information available at the end of the prior

---

[18]In Figure II, I show the post-transplant 1-year mortality from January 2001 to July 2007 and illustrate the pre-CoP and post-CoP in my subsequent analysis.

six-month window. The linear equation below represents a static version of this economic model:

$$Y_{ickt} = \alpha_c + \delta_t + \sum_{s \in \{ann,imp\}} \beta_s \mathbb{E}[\mathbf{1}(\mathbf{CoP_{ct}} > \mathbf{\bar{CoP}})|I_{t-1}] \times \mathbf{1}(t = s) + X'_{ik}\gamma + \varepsilon_{ickt} \qquad (2)$$

Here, Y_{ickt} represents the outcome of interest, such as patient mortality, the primary performance metric for this discussion. α_c controls for time-invariant center characteristics, while δ_t accounts for common shocks affecting all centers within a six-month window. The key term captures the center's expectation of exceeding the unadjusted mortality cutoff based on its information set at the start of the six-month window. This forward-looking approach differs from prior studies, which focus on post-implementation behavior, and allows me to capture potential anticipatory responses during the 2.5 years between CoP's announcement and implementation[19]. The variable ε_{ickt} captures omitted factors affecting mortality, while X_{ik} accounts for patient and kidney risk factors. The parameter β_s measures the average change in outcomes after the CoP announcement or implementation when beliefs increased by 10 pp or one standard deviation.

5.1 Measure of center expectation

Center beliefs provide the key identifying variation across centers but remain unobserved. I make two simplifying assumptions to construct an empirical analog. I assume the center bases its expectation on knowledge of past mortality performance and transplant volume. I also assume that centers have rational expectations conditional on past performance.

I follow Gupta (2021) and non-parametrically predict an empirical analog of each center's expectation of being penalized in the future using a kernel regression of actual penalty status on the relevant unadjusted post-transplant mortality and transplant volume, as shown in equation 3.

$$\mathbb{E}[\mathbf{1}(\mathbf{CoP_{ct}} > \mathbf{\bar{CoP}})|I_{t-1}] = f(R_{c,t-1}, TX_{c,t-1}) + \xi_{ct}$$
$$\widehat{\mathbb{E}}[\mathbf{1}(\mathbf{CoP_{ct}} > \mathbf{\bar{CoP}})|I_{t-1}] = \widehat{f}(R_{c,t-1}, TX_{c,t-1}) \qquad (3)$$

---

[19]The potential penalties for non-compliance, such as system reviews, temporary shutdowns, and CMS decertification, provide strong incentives for the center to adjust its behavior in anticipation of CoP's implementation.

Conceptually, this expectation predicts the probability of a penalty for a center based on the experience of neighboring centers falling within the kernel bandwidth. I denote the predicted value from the kernel regression as $\rho_{c,t+2}$. One problem is that the flagging status released in July 2007 is not exogenous; it consists of transplants that coincide with the post-CoP announcement. To estimate the center's belief, I circumvented this issue using the flagging status in January 2005, July 2005, and January 2006. Their 2.5-year rolling cohort does not overlap with the CoP announcement. I illustrate this in Figure C.V. Hence, I calculate the probability of flagging using these penalty statuses and denote it as ρ_c.

Figure III: Density of center likelihood of future flagging

Note: This figure illustrates the density of the constructed continuously varying measure of a forward-looking center's expectation of being flagged in the future. The expectation, P_c, is predicted by the unadjusted mortality rate and transplant volume from 2005-2006.

In Figure III, the average (median) transplant center has a 10 (7)% probability of being flagged in the future. Using a similar approach to Gupta (2021), I estimate significantly lower penalty expectations than those observed in the Hospital Readmissions Reduction Program (HRRP), where approximately 50% of hospitals receive penalties. This discrepancy arises because Medicare penal-

izes hospitals in HRRP if their risk-adjusted 30-day readmission rates exceed the national average, resulting in a higher likelihood of a baseline penalty. In contrast, under CoP, centers must meet all three conditions outlined in Section 2.4 to be penalized, significantly lowering the expectation of penalties. Figure C.VI plots the density of beliefs, showing how penalty expectations in the CoP setting differ from those in HRRP. Additionally, condition 3 of the CoP is specifically designed to protect low-volume centers, which are more likely to exceed condition 1 (i.e., an observed-to-expected death ratio exceeding 1.5), thereby further reducing the likelihood of penalty.

Although the likelihood of penalties is relatively low, the expected loss for flagged centers is substantial. As discussed in Section 2.4, flagged centers must undergo a system review, and temporary shutdowns pose a significant opportunity cost to their profit margins. Moreover, centers flagged twice within 30 months face the threat of CMS decertification, which could effectively shut down their transplant operations. These sizeable potential losses provide strong incentives for centers to adjust their behavior, focusing on improving post-transplant outcomes and avoiding conditions that might trigger penalties.

5.2 Mean reversion

The OLS regression in the previous subsection could underestimate the effect of the CoP announcement due to the possibility of mean reversion (Chay, McEwan and Urquiola, 2005; Gupta, 2021). Transplant centers may have escaped penalty due to a temporary downswing in their mortality rate above their "true" mean, just as the flagging rate was first determined. They adjust their behavior, knowing that their performance will revert to their true, lower-quality self in the future. Hence, an OLS regression on center beliefs will suggest that the penalty did not motivate centers to improve. I overcame this concern by using an instrumental variables approach, relying on variation in center quality from 2002 to 2004, before the CoP announcement, to generate exogenous variation in penalty probability under CoP. This approach assumes that true hospital quality remains stable over time and utilizes historical features to predict the probability of flagging, thereby eliminating the impact of temporary fluctuations. Furthermore, the instrument is exogenous because it is

estimated using pre-CoP data and, therefore, is not influenced by contemporaneous policy changes.

This type of dynamic model has been extensively analyzed (Anderson and Hsiao, 1981; Amemiya and MaCurdy, 1986; Arellano and Bond, 1991). One solution to obtain a consistent estimate of β is to use baseline or "predetermined" characteristics of center c as instruments for ρ_c (Arellano and Bover, 1995; Acemoglu and Finkelstein, 2008; Gupta, 2021). Accordingly, I use a center-level instrument Z_c predicted using baseline covariates. The IV approach also mitigates concerns of measurement error in constructing center expectations.

Equation 5 presents the empirical version of the conceptual model in equation 2, where I replace the expectation term with the estimate obtained using equation 3. Equation 4 also contains the first-stage equation:

$$\rho_c \times \mathbb{1}(t = s) = \pi_c + \pi_t + \lambda Z_c \times \mathbb{1}(t = s) + u_{ickt} \quad ; \quad s \in \{ann, imp\} \tag{4}$$

$$Y_{ickt} = \alpha_c + \delta_t + \sum_{s \in \{ann,imp\}} \beta_s \widehat{\rho}_c \times \mathbb{1}(t = s) + X'_{ik}\gamma + \varepsilon_{ickt} \tag{5}$$

I estimate the two rows of equations jointly using two-stage least squares (2SLS), such that the endogenous variable, ρ_c, is replaced by the predicted value, $\widehat{\rho}_c$ generated using the first stage. The baseline instrument is an expected mortality rate using data on patient risk factors from 2002 - 2004. This is the earliest year for which data are available. The predicted value is, therefore, purged of unobserved factors and transient noise. The identifying assumption is that centers with low versus high values of expected mortality rates held constant as in 2005 would evolve along parallel trends in the absence of the CoP announcement. To explore the validity of this assumption, I plot the coefficients β_s obtained by estimating the following dynamic nonparametric equation:

$$Y_{ickt} = \alpha_h + \delta_t + \sum_{s \neq 2003h2} \beta_s \mathbf{1}(d_{Z_c=1}) \times \mathbf{1}(t = s) + \varepsilon_{ickt} \tag{6}$$

d_{Z_c} is an indicator set to 1 if center c is the top half of all centers, ranked by the instrument Z_c. Recall from previous discussions that the center with the highest historical mortality rate has the

highest penalty risk and, therefore, the most incentive to improve.

5.3   Subsample

To identify the causal effect of the CoP policy on post-transplant mortality, I rely on the sub-sample of patients whose post-transplant mortality timeline do not overlap with the CoP announcement. I exclude patients whose post-transplant timeline overlaps with the CoP announcement due to potential temporal confounding (i.e., post-transplant mortality risk naturally increases over time). This approach improves the study's internal validity by ensuring that I make comparisons between patients whose outcomes are exclusively influenced by pre- or post-CoP conditions. Figure C.VII illustrates the two kinds of patients discussed above.

The primary threat to the identification strategy is the possibility that the composition of patients across centers changed in significant and potentially unobservable ways. While Table D.III does not show clear evidence of such changes, this does not entirely rule out the concern. To address this, Section 6.2 provides additional analysis demonstrating that centers do not appear to systematically discriminate against specific patient profiles or kidney types at the transplant or admission stages. This combined evidence mitigates concerns about potential selection bias that could undermine the identification strategy.

6   Effects on post-transplant mortality and mechanisms

This section quantifies the effects of the CoP policy on post-transplant 1-year mortality, the program's targeted metric, to establish its top-line impact. Using patient-kidney offers and follow-up data, I then analyze how the selection and post-transplant care channel drive the changes in post-transplant mortality at different phases of the CoP policy, respectively.

Figure IV: Impact on post-transplant 1-year mortality

Note: The figure presents the estimated effects on the probability of post-transplant 1-year mortality, obtained using equation 6 with the instrument Z_h and 2003h2 as the reference 6-month window. The first dashed vertical line is the CoP announcement, and the second line is the CoP implementation. I use robust standard errors. Error bars indicate 95 percent confidence intervals.

6.1 Targeted metric

Figure IV plots the coefficients β_s of equation 6 for 6-month windows between 2001 and 2012, with 2003h2 as the reference period, to examine changes in the probability of post-transplant 1-year mortality. The plot reveals two key insights. First, no preexisting differential trends exist between centers with low and high values of Z_h, indicating that the parallel trends assumption might hold in my setting. Second, after the CoP announcement in February 2005 (first dashed vertical line), there was a statistically significant and economically meaningful decline in mortality for centers with higher penalty risks. The pattern persisted even when Medicare implemented CoP (second dashed vertical line). My results suggest that the no-anticipatory assumption in prior studies, which focus on behavior post-CoP implementation, may overlook essential center responses during the announcement period.

Table II presents OLS (Column 1) and IV (Column 2) estimates, showing a 2.78 pp reduction in post-transplant 1-year mortality for a one-standard-deviation increase in a center's belief after

Medicare announced CoP. The IV estimates are larger than the OLS estimates, consistent with concerns that mean reversion may underestimate the CoP response.

For context, in 2004, 11% of the 10,370 kidney transplant recipients died within a year. A 2.77 pp decline implies that 853 patients died post-transplant, compared to 1,147 previously—a 25% decrease. The improvements persisted even after Medicare implemented CoP in July 2007, though at a smaller magnitude (2.21 pp).

Table II: Impact on targeted metric, post-transplant 1-year mortality

	(1) OLS	(2) IV
Post-Announce	-0.01470***	-0.02777***
	(0.00423)	(0.00582)
Post-Implement	-0.01384***	-0.02212***
	(0.00375)	(0.00524)
Y mean	0.11036	0.11036
F-statistic		14713.68470
Fixed Effects	Center, 6-months	Center, 6-months
Observations	105264	105264

Note: This table presents an estimated effect on the probability of post-transplant 1-year mortality, obtained by estimating equation 5 (1st column, OLS) and jointly estimating equations 4, 5 (2nd column, IV), respectively on the subsample of patients whose post-transplant mortality timeline do not overlap with the CoP announcement described in Section 5.3. I use robust standard errors.*$p < 0.1$, **$p < 0.05$, ***$p < 0.01$.

Further analysis in Figure C.VIII and Table D.IV, using granular time intervals, shows that mortality improvements are most pronounced within the first two weeks and six months after receiving a kidney transplant. This suggests that transplant centers concentrated their mitigation efforts on these critical periods, such as closer monitoring and an adjusted immunosuppressant regimen. While early and intermediate post-transplant periods show substantial improvements, the policy had little or no effect on mortality beyond two years. These findings suggest that CoP significantly improved early transplant outcomes and that centers prioritize immediate and intermediate recovery stages to achieve these gains. In the following subsection, I examine how both selection and post-transplant care channels contributed to the improvements in post-transplant mortality.

6.2 Selection channel

Quantifying the role, if any, of distortions in producing the decline in post-transplant 1-year mortality reported above is vital. This subsection examines how centers select patients and kidneys for transplantation and their effect on kidney utilization.

6.2.1 Selection into transplant

Figure V: Impact on patient-kidney offer acceptance

Note: The figure presents the estimated effects on the probability of accepting a patient-kidney offer, obtained using equation 6 with the instrument Z_h and 2003h2 as the reference 6-month window. I use robust standard errors. Error bars indicate 95 percent confidence intervals.

The CoP penalty reduces the financial attractiveness of performing transplants, incentivizing centers to accept fewer patient-kidney offers and potentially wait for better matches to minimize post-transplant mortality. Figure V plots the estimated effects on acceptance probabilities for patient-kidney pairs in each 6-month window, using equation 6 with an acceptance indicator, A_{ickt}, as the dependent variable. The figures show that centers expecting greater penalties decreased acceptance rates for patient-kidney pairs after the CoP announcement. However, acceptance rates for these centers were already trending lower in 2004, suggesting that pre-existing trends may partly

explain the observed changes. The trend flattened after Medicare implemented CoP, highlighting a potential stabilization in acceptance behavior. On average, Table III indicates a 1.42 pp decline in acceptance probability, corresponding to a 7% decrease given the mean acceptance rate of 20 pp, after CMS announced CoP.

To examine whether centers avoided specific patient or kidney profiles to reduce mortality risk, I estimated triple-difference models that interact center penalty risk with predetermined patient and kidney risk measures [20]. These models test whether acceptance probabilities changed more for high-risk profiles than low-risk ones. Columns 3–5 in Table III show that the triple-difference coefficients are statistically insignificant, suggesting that centers did not systematically avoid riskier profiles [21].

Table III: Impact on selection into transplant

	Accept Decision (DiD)		Accept Decision across subgroups (Triple DiD))		
	(1)	(2)	(3)	(4)	(5)
	OLS	IV	Risky Pat.	Risky Kid.	Risky Pat.x Kid.
Post-Ann	-0.00983***	-0.01424***	-0.01125**	-0.01440*	-0.01170**
	(0.00105)	(0.00160)	(0.00412)	(0.00660)	(0.00436)
Post-Imp	-0.00953***	-0.00525***	-0.01152*	-0.01033	-0.01054
	(0.00099)	(0.00159)	(0.00544)	(0.00782)	(0.00580)
Post-Ann (Tri)			0.00509	0.00867	0.00795
			(0.00536)	(0.00553)	(0.00497)
Post-Imp (Tri)			0.00429	0.00256	0.00199
			(0.00437)	(0.00597)	(0.00482)
Y mean	0.19991	0.19991	0.19991	0.19991	0.19991
F-statistic		85350.65540			
Fixed Effects	Center, 6-months	Center, 6-months	Center, 6-months	Center, 6-months	Center, 6-months
Observations	874517	874517	874517	874517	874517

Note: This table presents an estimated effect on the probability of accepting a patient-kidney offer, obtained using equation 2 (1st column, OLS) and 4 (2nd column, IV). Columns 3, 4, and 5 are estimates from triple differences regression interacted with patient, kidney, and patient-kidney risk profiles. I use robust standard errors. *$p < 0.1$, **$p < 0.05$, *** $p < 0.01$

---

[20] I use the kidney donor profile index (KDPI) and estimated post-transplant survival (EPTS) as measures of kidney and patient risk, respectively. A kidney is high-risk if $KDPI \geq 0.5$, and a patient is high-risk if $EPTS \geq 0.5$. A patient-kidney pair is considered high-risk if both the patient and the kidney are high-risk.

[21] In the Appendix, I run similar triple-difference regressions interacting with various patient and kidney characteristics and find no statistically significant results in Tables D.XI and D.XII.

6.2.2 Kidney discard

While CoP incentivized centers to become less likely to accept a given patient-kidney pair, OPTN only discards deceased donor kidneys if no center is willing to transplant them. I examine the broader implications of CoP on kidney utilization, a metric emphasized in the recent Biden-Harris administration's "Increased Organ Transplantation Access (IOTA)" model (CMS, 2024).

Each discarded kidney represents a missed opportunity to save or improve a patient's life, particularly given the significant organ shortage and growing number of patients on the waitlist[22]. While some kidneys are discarded due to legitimate medical concerns, such as poor quality or high risk of complications, a substantial proportion of discarded kidneys might still be viable for transplantation. Factors such as center preferences, risk aversion, and systemic inefficiencies can influence these decisions, potentially leading to avoidable waste. Analyzing kidney discard patterns is essential to identify whether CoP unintentionally exacerbates these issues by incentivizing overly cautious behavior.

To investigate this, I aggregate data on all patient-kidney offers to the kidney level and construct a weighted average of center penalty exposure, $Exposure_k$ [23]. The following equation represents the discard model:

$$D_{kdt} = \alpha_d + \delta_t + \sum_{s \in \{ann, imp\}} \beta_s Exposure_k \times \mathbf{1}(t = s) + X_k'\gamma + \varepsilon_{kt} \qquad (7)$$

Here, D_{kdt} is the discard indicator, α_d represents donor service area fixed effects, δ_t accounts for six-month window fixed effects, and X_k is a vector of kidney characteristics. The parameter of interest, β_s, captures whether kidneys offered to more exposed centers are more likely to be discarded after the CoP announcement or implementation. Table D.XVI presents the results. Column 1 finds no statistically significant increase in overall kidney discard rates after CoP implementation. Column 2, which introduces a triple-difference specification interacting exposure with a high-risk kidney indicator, suggests that high-risk kidneys were 3.6 pp (23.1%) more likely to be discarded

---

[22]Nearly 30% of recovered kidneys are discarded each year (McKenney et al., 2024).
[23]I use the proportion of patients from the same transplant center as weights.

than low-risk kidneys following Medicare's CoP announcement. However, this effect attenuated after CoP implementation, suggesting an adaptive response among transplant centers.

Columns 3 and 4 examine the number of patients offered high-risk kidneys to explore the mechanism behind this trend. Following Medicare's CoP announcement, high-risk kidneys were offered to 35.8 patients, a 13.2% increase relative to low-risk kidneys, suggesting greater difficulty finding an accepting center. However, post-implementation, high-risk kidneys were offered to 95.7 fewer patients (a 35.4% relative decrease), indicating that centers became more receptive.

These findings suggest that the initial increase in high-risk kidney discards was driven by uncertainty and unfamiliarity with the CoP policy. In the period immediately following the announcement, transplant centers exercised greater caution, leading to increased rejection rates. However, as centers adapted to the policy, the discard rate of high-risk kidneys converged toward that of low-risk kidneys. These results highlight a temporary adjustment period in response to policy change.

6.3 Post-transplant care channel

In Section 3, I presented a stylized model describing the center's incentives and how CoP affects the center's behavior. Under this model, optimal post-transplant care, $q^*(x)$, will equate the marginal cost of incremental care with the marginal benefit to the patient and center. CoP incentivizes centers to provide optimal post-transplant care, thereby decreasing the patient's probability of post-transplant mortality and, in turn, the center's likelihood of exceeding the CoP threshold. Hence, CoP nudges the center to increase post-transplant care on average (i.e., $\frac{\partial q^*(x)}{\partial \tau} > 0$).

I use novel follow-up data that track patient immunosuppressant prescriptions and outcomes of medical tests performed during revisits to examine how CoP affects post-transplant care. I focus on how centers prevent kidney rejection and detect viral infections, as mentioned in Section 2.3.

6.3.1 Prevention

The immune system naturally fights against foreign objects in the body, which poses a challenge to kidney transplant patients, as the immune system often recognizes the new kidney as for-

eign and attempts to reject it. Immunosuppressants are necessary to prevent acute kidney rejection by suppressing the patient's immune system and reducing the likelihood of an immune attack. Three kinds of immunosuppressants are used at different stages of the transplant process: (i) *induction medicine,* a potent anti-rejection medicine administered intravenously around the time of transplant to prepare the patient's immune system for the new kidney; (ii) *maintenance medicine,* which are taken continuously to manage immune activity and prolong graft viability; (iii) *rejection medicines,* which are used to treat episodes of rejection when they occur[24]. This subsection focuses on maintenance medicines.

Figure VI: Impact on maintenance immunosuppressant prescription at different follow-up periods

Note: The figure presents the estimated effects on the probability of prescribing maintenance immunosuppressant at different follow-up periods, obtained using equation 6 with the instrument Z_h and 2003h2 as the reference 6-month window. The first dashed vertical line is the CoP announcement, and the second line is the CoP implementation. I use robust standard errors. Error bars indicate 95 percent confidence intervals.

Figure VI presents an event study analysis of maintenance immunosuppressant prescription rates at 2-week, 6-month, and 1-year follow-ups across different phases of the CoP policy. Immediately following the CoP announcement, prescription rates remained unchanged at all subsequent follow-up intervals. However, as the CoP implementation date approached (second dashed vertical

---

[24]Source: UNOS, types of immunosuppresants

line), maintenance immunosuppressant prescriptions increased for patients attending their 2-week or 6-month post-transplant follow-up. This trend intensified after CMS implemented CoP. For example, column 2 of Table D.V shows that 6-month maintenance immunosuppressant prescription rose by 5.34 pp, an 8% increase given the mean prescription rate of 66 pp [25].

These patterns suggest that as centers became more familiar with CoP enforcement criteria, they shifted from avoiding high-risk kidney matches to offsetting transplant risks through better post-transplant care. Specifically, increased immunosuppressant prescriptions likely reduced the probability of rejection for higher-risk kidney matches. Notably, the range of maintenance immunosuppressants remained relatively stable during the analysis period (2001-2012), with no significant breakthrough in drug efficacy (Cooper, 2020). This stability further emphasizes that the observed prescription changes reflect clinicians optimizing post-transplant care through drug prescription rather than responding to new pharmaceutical developments. Finally, no significant changes were observed in 1-year immunosuppressant prescriptions, indicating that centers primarily focused on making short- and medium-term adjustments to prescriptions rather than long-term treatment protocols.

6.3.2 Detection

Cytomegalovirus (CMV) is one of the primary agents responsible for infectious complications following transplantation. This infection occurs due to transmission from the transplanted organ or due to taking drugs to suppress the immune system from attacking the foreign kidney (Azevedo et al., 2015; Pilch, Bowman and Taber, 2020). The CMV test detects the presence of antibodies against CMV, a virus that can reactivate in immunosuppressed kidney transplant recipients, potentially triggering immune activation leading to rejection. Regular CMV testing enables early identification of viral infections, allowing for timely antiviral treatment to prevent immune-mediated damage (Hasanzamani et al., 2016).

Figure VII presents an event study analysis of CMV testing rates at 2-week, 1-year, and 2-year

---

[25]Follw-up data only capture prescription status but not drug dosage; thus, I cannot assess intensive margin changes.

Figure VII: Impact on CMV serology test at different follow-up periods

Note: The figure presents the estimated effects on the probability of performing a CMV serology test at different follow-up periods, obtained using equation 6 with the instrument Z_h and 2003h2 as the reference 6-month window. The first dashed vertical line is the CoP announcement, and the second line is the CoP implementation. I use robust standard errors. Error bars indicate 95 percent confidence intervals.

follow-ups across different phases of the CoP policy. The results reveal distinct patterns in testing practices across the three follow-up periods. First, transplant centers did not significantly alter CMV testing protocols at the 2-week follow-up. This consistency is expected, as early CMV testing is a standard post-transplant procedure designed to ensure patient stability and detect immediate complications. Since this practice was already well-established, centers had little reason to modify it in response to the CoP announcement or implementation[26]

In contrast, CMV testing rates increased substantially at 1-year and 2-year follow-ups after CMS announced and implemented CoP. For example, column 2 of Table D.VII shows that 1-year CMV testing rose by 4.2 pp, a 14.5% increase relative to a baseline mean of 28.3 pp. This pattern suggests that centers, anticipating greater regulatory scrutiny under CoP, expanded testing to detect viral infections better and manage immunosuppressant side effects. Consistent with this response, Table D.VIII documents a corresponding decline in infection-related deaths over the same period.

---

[26]Source: Managing Kidney Transplant Recipients.

Overall, these patterns highlight how regulatory oversight not only altered standard short-term practices but also incentivized centers to expand long-term infection surveillance. The observed increase in late-stage CMV testing, coupled with a reduction in infection-related mortality, illustrates how targeted quality oversight can incentivize meaningful clinical improvements beyond immediate transplant outcomes.

7 Robustness checks

This section discusses alternative selection mechanisms and tests the sensitivity of the estimates to modeling assumptions.

7.1 Alternative selection mechanisms

7.1.1 Donor filtering

In Section 2.1, centers register patients onto the national waitlist and upload relevant medical and biological information. Simultaneously, centers can proactively filter potential donors for patients in the UNet system (King et al., 2022; Yu et al., 2024). For instance, a center might impose a maximum donor age, thereby preventing offers from donors who exceed this criterion, regardless of biological compatibility. Using patients' waitlist records, I document all modifications to donor criteria made during the patients' waitlist periods to analyze whether these adjustments reflect strategic donor filtering. The hypothesis is that CoP could incentivize centers to avoid risky kidney profiles by imposing stricter donor criteria.

To identify this effect, I leverage patients whose waitlist tenure overlaps with the CoP announcement and subsequent implementation. Using a patient fixed-effects regression, I isolate the impact of CoP on donor filtering by examining within-patient changes in donor criteria[27]. The following equation represents the donor filtering model:

---

[27]To minimize potential temporal confounds-specifically, that centers might naturally become less restrictive as patients' waiting time increases-I limit the analysis to patients listed from 2004 to 2012, who had waited fewer than six months and subsequently remained on the waitlist for at least three additional years.

$$Y_{ict} = \alpha_i + \delta_t + \sum_{s \in \{ann, imp\}} \beta_s \widehat{\rho}_c \times \mathbb{1}(t = s) + X'_{it}\gamma + \varepsilon_{ict} \qquad (8)$$

Here, Y_{ict} represents various donor criteria, such as age, BMI, and human leukocyte antigen mismatches, among others. α_i controls for time-invariant patient characteristics, while δ_t accounts for common shocks affecting all patients within a quarter. Tables D.IX and D.X present estimates for various modifiable donor characteristics[28]. The analysis reveals no consistent evidence that centers tighten donor criteria in response to CoP; instead, centers appeared to loosen specific criteria (e.g., accepting higher creatinine levels and longer ischemic times) to broaden their available kidney pool.

7.1.2 Strategic admission

Another way centers could influence post-transplant outcomes is by altering the patient population they admit. For example, White et al. (2014) suggests that centers may adopt more conservative admission criteria based on the belief that socioeconomic factors affect patients' ability to comply with post-transplant care instructions[29]. I examine various socio-economic and health indicators among admitted patients to test this hypothesis. As shown in Tables D.XIV and D.XV, the analysis reveals no significant changes in these characteristics after the CoP announcement, suggesting that centers did not modify their admission strategies significantly based on socioeconomic and health factors.

CoP penalizes centers for post-transplant mortality but not waitlist mortality. Consequently, admitting a patient may represent a low-commitment action for centers, as it does not obligate them to proceed with a transplant or directly affect their performance metrics under CoP. This lack of immediate accountability might explain why admission practices remained unchanged despite the CoP announcement and implementation.

---

[28]Some criteria (e.g., diabetes, obesity, outside of donor service area and death by cardiac arrest) were omitted from the tables because they were never modified and were often set to the upper bound, further emphasizing the lack of desire to omit these potentially undesirable kidneys.

[29]White et al. (2014) uses within-center temporal variation to analyze flagged centers' patient admission strategies.

7.2 Robustness checks

I test the sensitivity to changing key modeling assumptions. First, I use the entire patient sample and include patients whose post-transplant mortality timeline overlaps with the CoP announcement. Table D.XVII reproduces the coefficients for equation 5 using outcome variables: post-transplant mortality, CMV testing, and immunosuppressant prescription. The estimates are similar to the specifications where I omit the overlapping patients.

Second, I use an alternate approach to construct center-flagging beliefs. A useful benchmark is to assume that centers had perfect foresight and accurately predicted their actual flagging status in July 2007 under CoP. This is straightforward to implement by replacing the flagging probabilities with actual first-time flagging status indicators in equation 5. Table D.XVIII has estimates that remain largely unaffected, except for the columns on the prescription of immunosuppressants.

Third, I also change the main specification, allowing the center flagging probability to vary over time. Then, I include this measure in the model along with the interaction term and estimate a standard differences-in-differences specification. The estimates in Table D.XIX are considerably smaller. Still, they remain statistically significant for most cases[30].

8 Conclusion

This paper examines a large-scale federal oversight program in the U.S. deceased donor kidney transplant setting. While the CoP policy reduced post-transplant mortality rates by 20-25%, the mechanisms driving these improvements evolved across different phases of the CoP policy. Initially, centers became more conservative in transplanting a given patient-kidney pair. This cautious approach resulted in more high-risk kidneys being discarded and a reduction in mortality due to fewer risky transplants. Over time, as centers became more familiar with the policy's details,

---

[30]A weakness of this approach is that the beliefs computed for later periods rely on performance after the first penalty status was known. If flagged centers responded by differentially lowering their mortality rate, their beliefs would decrease in subsequent years, and the model will estimate a lower differential response across centers. Hence, this approach may understate the true response, but it still offers a useful specification check.

they restored transplant volumes and increased immunosuppressant prescriptions to prevent kidney rejection. Furthermore, they complemented these efforts with enhanced viral infection testing to manage side effects related to immunosuppression.

While the results highlight some inefficiencies in kidney utilization following the announcement, they demonstrate that CoP successfully shifted transplant centers toward improving post-transplant care rather than simply avoiding the risky transplants. Three key factors likely contributed to this success. First, the incentive structure of CoP was carefully designed, with sufficiently large penalties to prompt action while protecting vulnerable centers from disproportionate risks. Second, the 2.5-year gap between the program's announcement and implementation gave centers time to learn the policy's nuances and refine their practices to reduce post-transplant mortality. Third, frequent communication between CMS and centers during this period fostered a collaborative environment, emphasizing guidance and improvement rather than punitive measures (Abecassis et al., 2008).

The findings point to several directions for future research. The analysis highlights the broader potential of integrating policy design with mechanism design to address inefficiencies in the deceased donor kidney program. Exploring how such frameworks can be expanded to other aspects of organ allocation and post-transplant care could yield valuable insights for improving system-wide outcomes.

References

Abecassis, M.M., R. Burke, A.B. Cosimi, A.J. Matas, R.M. Merion, D. Millman, J.P. Roberts, and G.B. Klintmalm. 2008. "Transplant Center Regulations—A Mixed Blessing? An ASTS Council Viewpoint." *American Journal of Transplantation*, 8(12): 2496–2502.

Acemoglu, Daron, and Amy Finkelstein. 2008. "Input and Technology Choices in Regulated Industries: Evidence from the Health Care Sector." *Journal of Political Economy*, 116(5): 837–880.

Agarwal, Nikhil, Charles Hodgson, and Paulo Somaini. 2020. "Choices and Outcomes in Assignment Mechanisms: The Allocation of Deceased Donor Kidneys." National Bureau of Economic Research Working Paper 28064.

Agarwal, Nikhil, Itai Ashlagi, Michael A. Rees, Paulo Somaini, and Daniel Waldinger. 2021. "Equilibrium Allocations Under Alternative Waitlist Designs: Evidence From Deceased Donor Kidneys." *Econometrica*, 89(1): 37–76.

Al Atbee, Mohammed Younus Naji, and Hala Sami Tuama. 2022. "Cytomegalovirus infection after renal transplantation." *Journal of Medicine and Life*, 15(1): 71–77.

Alexander, Diane. 2020. "How Do Doctors Respond to Incentives? Unintended Consequences of Paying Doctors to Reduce Costs." *Journal of Political Economy*, 128(11): 4046–4096.

Amemiya, Takeshi, and Thomas E. MaCurdy. 1986. "Instrumental-Variable Estimation of an Error-Components Model." *Econometrica*, 54(4): 869–880.

American Kidney Fund (AKF). 2008. "Deceased donor kidney transplants."

Anderson, T. W., and Cheng Hsiao. 1981. "Estimation of Dynamic Models with Error Components." *Journal of the American Statistical Association*, 76(375): 598–606.

Arellano, Manuel, and Olympia Bover. 1995. "Another look at the instrumental variable estimation of error-components models." *Journal of Econometrics*, 68(1): 29–51.

Arellano, Manuel, and Stephen Bond. 1991. "Some Tests of Specification for Panel Data: Monte Carlo Evidence and an Application to Employment Equations." *The Review of Economic Studies*, 58(2): 277–297.

Azevedo, Luiz Sergio, Lígia Camera Pierrotti, Edson Abdala, Silvia Figueiredo Costa, Tânia Mara Varejão Strabelli, Silvia Vidal Campos, Jéssica Fernandes Ramos, Acram Zahredine Abdul Latif, Nadia Litvinov, Natalya Zaidan Maluf, Helio Hehl Caiaffa Filho, Claudio Sergio Pannuti, Marta Heloisa Lopes, Vera Aparecida dos Santos, Camila da Cruz Gouveia Linardi, Maria Aparecida Shikanai Yasuda, and Heloisa Helena de Sousa Marques. 2015. "Cytomegalovirus infection in transplant recipients." *Clinics*, 70(7): 515–523.

Bae, Hannah. 2024. "Can Redrawing Boundaries Save Lives? Evidence from a Reform of the Kidney Allocation System." *Working Paper*.

Becker, Jan Ulrich, Daniel Seron, Marion Rabant, Candice Roufosse, and Maarten Naesens. 2022. "Evolution of the Definition of Rejection in Kidney Transplantation and Its Use as an Endpoint in Clinical Trials." *Transplant International*, 35.

Bloch, Francis, and David Cantala. 2017. "Dynamic Assignment of Objects to Queuing Agents." *American Economic Journal: Microeconomics*, 9(1): 88–122.

Bundorf, M. Kate, Natalie Chun, Gopi Shah Goda, and Daniel P. Kessler. 2009. "Do markets respond to quality information? The case of fertility clinics." *Journal of Health Economics*, 28(3): 718–727.

Center for Medicaid and Medicare Services. 2024. "Biden-Harris Administration Finalizes New Model to Improve Access to Kidney Transplants | CMS — cms.gov." *https://www.cms.gov/newsroom/press-releases/biden-harris-administration-finalizes-new-model-improve-access-kidney-transplants*, [Accessed 06-01-2025].

Chay, Kenneth Y., Patrick J. McEwan, and Miguel Urquiola. 2005. "The Central Role of Noise in Evaluating Interventions That Use Test Scores to Rank Schools." *American Economic Review*, 95(4): 1237–1258.

Clemens, Jeffrey, and Joshua D. Gottlieb. 2014. "Do Physicians' Financial Incentives Affect Medical Treatment and Patient Health?" *American Economic Review*, 104(4): 1320–49.

Cooper, James E. 2020. "Evaluation and Treatment of Acute Rejection in Kidney Allografts." *Clinical Journal of the American Society of Nephrology*, 15(3): 430–438.

Cox, D. R. 1972. "Regression Models and Life-Tables." *Journal of the Royal Statistical Society. Series B (Methodological)*, 34(2): 187–220.

Dickert-Conlin, Stacy, Todd Elder, and Keith Teltser. 2019. "Allocating Scarce Organs: How a Change in Supply Affects Transplant Waiting Lists and Transplant Recipients." *American Economic Journal: Applied Economics*, 11(4): 210–39.

Dickinson, D. M., C. J. Arrington, G. Fant, G. N. Levine, D. E. Schaubel, T. L. Pruett, M. S. Roberts, and R. A. Wolfe. 2008. "SRTR program-specific reports on outcomes: A guide for the new reader." *American Journal of Transplantation*, 8(4 PART 2): 1012–1026.

Dickstein, Michael. 2017. "Physician vs. patient incentives in prescription drug choice." *Working Paper*.

Doval, Laura, Federico Echenique, Huang Wanying, and Yi Xin. 2024. "Social Learning in Lung Transplant Decision."

Dranove, David, and Ginger Zhe Jin. 2010. "Quality Disclosure and Certification: Theory and Practice." *Journal of Economic Literature*, 48(4): 935–63.

Dranove, David, Daniel Kessler, Mark McClellan, and Mark Satterthwaite. 2003. "Is More Information Better? The Effects of "Report Cards" on Health Care Providers." *Journal of Political Economy*, 111(3): 555–588.

Eliason, Paul J, Benjamin Heebsh, Ryan C McDevitt, and James W Roberts. 2019. "How Acquisitions Affect Firm Behavior and Performance: Evidence from the Dialysis Industry*." *The Quarterly Journal of Economics*, 135(1): 221–267.

Federal Register. 2005. "Medicare program; hospital conditions of participation: requirements for approval and re-approval of transplant centers to perform organ transplantation. Final Rule(42 CFR405, 482, 488,

and 498)." *https://www.govinfo.gov/content/pkg/FR-2005-02-04/pdf/05-1696.pdf*, [Accessed 11-12-2024].

Federal Register. 2007. "Medicare program; hospital conditions of participation: requirements for approval and re-approval of transplant centers to perform organ transplantation. Final Rule(42 CFR405, 482, 488, and 498)." *https://www.govinfo.gov/content/pkg/FR-2007-03-30/pdf/07-1435.pdf*, [Accessed 11-12-2024].

Feng Lu, Susan. 2012. "Multitasking, Information Disclosure, and Product Quality: Evidence from Nursing Homes." *Journal of Economics amp; Management Strategy*, 21(3): 673–705.

Gjertson, David W., Dorota M. Dabrowska, Xingping Cui, and J. Michael Cecka. 2002. "Four Causes of Cadaveric Kidney Transplant Failure: A Competing Risk Analysis." *American Journal of Transplantation*, 2(1): 84–93.

Gupta, Atul. 2021. "Impacts of Performance Pay for Hospitals: The Readmissions Reduction Program." *American Economic Review*, 111(4): 1241–83.

Hamilton, Thomas E. 2013. "Regulatory oversight in transplantation: are the patients really better off?" *Current Opinion in Organ Transplantation*, 18(2): 203–209.

Hasanzamani, Boshra, Maryam Hami, Vajihe Zolfaghari, Mahtab Torkamani, Mahin Ghorban Sabagh, and Saiideh Ahmadi Simab. 2016. "The effect of cytomegalovirus infection on acute rejection in kidney transplanted patients." *Journal of Renal Injury Prevention*, 5(2): 85–88.

Husain, Syed Ali, Jordan A. Rubenstein, Seshma Ramsawak, Anne M. Huml, Miko E. Yu, Lindsey M. Maclay, Jesse D. Schold, and Sumit Mohan. 2025. "Patient and Provider Attitudes Towards Patient-Facing Kidney Organ Offer Reporting." *Kidney International Reports*.

Jin, Ginger Zhe, and Alan T. Sorensen. 2006. "Information and consumer choice: The value of publicized health plan ratings." *Journal of Health Economics*, 25(2): 248–275.

King, Kristen L., S. Ali Husain, David J. Cohen, Jesse D. Schold, and Sumit Mohan. 2022. "The role of bypass filters in deceased donor kidney allocation in the United States." *American Journal of Transplantation*, 22(6): 1593–1602.

King, Kristen L., S. Ali Husain, Miko Yu, Joel T. Adler, Jesse Schold, and Sumit Mohan. 2023. "Characterization of Transplant Center Decisions to Allocate Kidneys to Candidates With Lower Waiting List Priority." *JAMA Network Open*, 6(6): e2316936–e2316936.

Kolstad, Jonathan T. 2013. "Information and Quality When Motivation Is Intrinsic: Evidence from Surgeon Report Cards." *American Economic Review*, 103(7): 2875–2910.

Leshno, Jacob D. 2022. "Dynamic Matching in Overloaded Waiting Lists." *American Economic Review*, 112(12): 3876–3910.

López-Oliva, María Ovidia, Julio Flores, Rosario Madero, Fernando Escuin, María José Santana, Teresa Bellón, Rafael Selgas, and Carlos Jiménez. 2017. "Cytomegalovirus infection after kidney transplantation and long-term graft loss." *Nefrología (English Edition)*, 37(5): 515–525.

Matas, Arthur J, and Mark Schnitzler. 2004. "Payment for Living Donor (Vendor) Kidneys: A Cost-Effectiveness Analysis." *American Journal of Transplantation*, 4(2): 216–221.

McKenney, Ceilidh, Julia Torabi, Rachel Todd, M. Zeeshan Akhtar, Fasika M. Tedla, Ron Shapiro, Sander S. Florman, Matthew L. Holzner, and L. Leonie van Leeuwen. 2024. "Wasted Potential: Decoding the Trifecta of Donor Kidney Shortage, Underutilization, and Rising Discard Rates." *Transplantology*, 5(2): 51–64.

Organ Procurement Transplantation and Network (OPTN). 2023. "Policies."

Pilch, Nicole A., Lyndsey J. Bowman, and David J. Taber. 2020. "Immunosuppression trends in solid organ transplantation: The future of individualization, monitoring, and management." *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*, 41(1): 119–131.

Purnell, Tanjala S., and Mara McAdams-DeMarco. 2020. "The Long Road to Kidney Transplantation: Does Center Distance Impact Transplant Referral and Evaluation?" *Clinical Journal of the American Society of Nephrology*, 15(4): 453–454.

Ramanarayanan, Subbu, and Jason Snyder. 2012. "Information Disclosure and Firm Performance: Evidence from the Dialysis Industry." *SSRN Electronic Journal*.

Roth, A. E., T. Sonmez, and M. U. Unver. 2004. "Kidney Exchange." *The Quarterly Journal of Economics*, 119(2): 457–488.

Sack, Kevin. 2012. "In Discarding of Kidneys, System Reveals Its Flaws." *The New York Times*. [Accessed 11-12-2024].

Sawani, Jina. 2019. "U.S. Renal Data System 2019 annual data report: Epidemiology of kidney disease in the United States — michiganmedicine.org." *https://www.michiganmedicine.org/news-release*, [Accessed 11-12-2024].

Schaffhausen, Cory R, Marilyn J Bruin, Warren T McKinney, Jon J Snyder, Arthur J Matas, Bertram L Kasiske, and Ajay K Israni. 2019. "How patients choose kidney transplant centers: A qualitative study of patient experiences." *Clin. Transplant.*, 33(5): e13523.

Schold, J.D., L.D. Buccini, T.R. Srinivas, R.T. Srinivas, E.D. Poggio, S.M. Flechner, C. Soria, D.L. Segev, J. Fung, and D.A. Goldfarb. 2013. "The Association of Center Performance Evaluations and Kidney Transplant Volume in the United States." *American Journal of Transplantation*, 13(1): 67–75.

Schold, Jesse D., Charlotte J. Arrington, and Greg Levine. 2010. "Significant Alterations in Reported Clinical Practice Associated with Increased Oversight of Organ Transplant Center Performance." *Progress in Transplantation*, 20(3): 279–287.

Senanayake, Sameera, Nicholas Graves, Helen Healy, Keshwar Baboolal, Adrian Barnett, Matthew P. Sypek, and Sanjeewa Kularatna. 2020. "Deceased donor kidney allocation: an economic evaluation of contemporary longevity matching practices." *BMC Health Services Research*, 20(1).

Shi, Maggie. 2023. "Monitoring for Waste: Evidence from Medicare Audits." *The Quarterly Journal of Economics*, 139(2): 993–1049.

Stith, Sarah S., and Richard A. Hirth. 2016. "The Effect of Performance Standards on Health Care Provider Behavior: Evidence from Kidney Transplantation." *Journal of Economics amp; Management Strategy*, 25(4): 789–825.

Su, Xuanming, and Stefanos A. Zenios. 2005. "Patient Choice in Kidney Allocation: A Sequential Stochastic Assignment Model." *Operations Research*, 53(3): 443–455.

Sweat, Kurt. 2024. "Endogenous Priority in Centralized Matching Markets: The Design of the Heart Transplant Waitlist." *Working Paper*.

United States Government Accountability Office. 2008. "Organ Transplant Programs, federal agencies have acted to improve oversight but implementation issues remain." *https://www.gao.gov/assets/gao-08-412.pdf*, [Accessed 11-12-2024].

Vatter, Benjamin. 2023. "Quality Disclosure and Regulation: Scoring Design in Medicare Advantage." *SSRN Electronic Journal*.

White, Sarah L., Dawn M. Zinsser, Matthew Paul, Gregory N. Levine, Tempie Shearon, Valarie B. Ashby, John C. Magee, Yi Li, and Alan B. Leichtman. 2014. "Patient Selection and Volume in the Era Surrounding Implementation of Medicare Conditions of Participation for Transplant Programs." *Health Services Research*, 50(2): 330–350.

Yu, Miko, Kristen L. King, S. Ali Husain, Jesse D. Schold, and Sumit Mohan. 2024. "Use of Offer Bypass Filters under the Circular Kidney Allocation System." *Kidney360*, 5(5): 756–758.

Zhang, Juanjuan. 2010. "The Sound of Silence: Observational Learning in the U.S. Kidney Market." *Marketing Science*, 29(2): 315–335.

A   Stylized model of center behavior without kidney choices

This section provides the proof for Propositions 1 and 2 in Section 3. The center chooses its transplant decision $A(\tilde{x})$ and post-transplant care $q(x)$ to maximize its expected payoff:

$$\max_{A(\tilde{x}), q(x)} \int_{\tilde{x}} A(\tilde{x}) \int_x \overbrace{\left[\rho \underbrace{\overbrace{[\pi + \alpha q(x)]}^{\text{center profit}}}_{} + (1-\rho) \overbrace{\left[xq(x) - \frac{\gamma}{2} q^2(x) \right]}^{\text{patient utility}} \right]}^{\Pi(x, q(x))} p(x|\tilde{x}) dx dF(\tilde{x})$$

(9)

$$\text{s.t.} \int_{\tilde{x}} A(\tilde{x}) \left[\int_x P(x, q(x)) p(x|\tilde{x}) dx \right] dF(\tilde{x}) \leq \tau$$

We solve the maximization problem via backwards induction.

A.1   Solving for $q^*(x)$

Let $\lambda \geq 0$ be the Lagrange multiplier on the constraint. Define the Lagrangian:

$$\mathcal{L} = \int_{\tilde{x}} A(\tilde{x}) \int_x \left[\Pi(x, q(x)) \right] p(x|\tilde{x}) dx \, dF(\tilde{x}) \; - \; \lambda \left[\int_{\tilde{x}} A(\tilde{x}) \int_x P(x, q(x)) p(x|\tilde{x}) dx dF(\tilde{x}) - \tau \right].$$

Step 1: If the constraint is slack ($\lambda = 0$).   For each x, we differentiate $\Pi(x, q(x))$ with respect to $q(x)$:

$$\rho \, \alpha + (1-\rho) \big[x - \gamma \, q(x) \big] = 0 \quad \Longrightarrow \quad (1-\rho) \, \gamma \, q(x) = \rho \, \alpha + (1-\rho) \, x.$$

Hence

$$q^{\text{uncon}}(x) = \frac{\rho \, \alpha + (1-\rho) \, x}{(1-\rho) \, \gamma}.$$

Step 2: If the constraint binds ($\lambda > 0$).   For each x, we need

$$\frac{\partial \mathcal{L}}{\partial q} = \int A(\tilde{x})\frac{\partial \Pi(.)}{\partial q}p(x|\tilde{x})dx dF(\tilde{x}) - \lambda \int A(\tilde{x})\frac{\partial P(.)}{\partial q}p(x|\tilde{x})dF(\tilde{x}) = 0$$

where

$$\frac{\partial}{\partial q}\overbrace{\left\{\rho(\pi + \alpha\, q(x)) + (1-\rho)\big[x\, q(x) - \tfrac{\gamma}{2}q^2(x)\big]\right\}}^{\Pi(x,q(x))} = \rho\,\alpha + (1-\rho)\big[x - \gamma\, q\big].$$

and

$$\frac{\partial}{\partial q(x)}\overbrace{\Big[1 - \Phi\big(\tfrac{x+q(x)}{\sigma}\big)\Big]}^{P(x,q(x))} = -\,\phi\Big(\tfrac{x+q(x)}{\sigma}\Big)\frac{1}{\sigma},$$

Rearrange for $q^*(x)$:

$$(1-\rho)\,\gamma\,q^*(x) = \rho\,\alpha + (1-\rho)\,x + \lambda\,\frac{1}{\sigma}\,\phi\Big(\tfrac{x+q^*(x)}{\sigma}\Big).$$

Thus we have the *implicit* solution:

$$q^*(x) = \frac{\rho\,\alpha + (1-\rho)\,x}{(1-\rho)\,\gamma} + \frac{\lambda}{(1-\rho)\,\gamma\,\sigma}\,\phi\Big(\tfrac{x+q^*(x)}{\sigma}\Big). \tag{10}$$

If $\lambda = 0$, we revert to the unconstrained optimum. Otherwise, $q^*(x)$ exceeds the unconstrained level, reflecting a desire to reduce mortality.

A.2   Solving for the acceptance rule $A(\tilde{x})$

Define the net benefit function, $NB(\tilde{x})$

$$NB(\tilde{x}) = \int \Pi(x, q(x))p(x|\tilde{x})dx - \lambda \int P(x, q(x))p(x|\tilde{x})dx$$

Since the posterior distribution of $p(x|\tilde{x})$ is increasing in $\tilde{x}$, $NB(\tilde{x})$ is a monotonic function of $\tilde{x}$, $A^*(\tilde{x})$ takes the form of a cutoff strategy:

$$A^*(\tilde{x}) = \begin{cases} 1 & \text{if } \tilde{x} \geq t^* \\ 0 & \text{if } \tilde{x} < t^* \end{cases} \tag{11}$$

where t^* is such that $NB(t^*) = 0$. This completes the proof for proposition 1.

A.3 Comparative Statics: Effect of Decreasing τ

As τ decreases, the regulatory constraint tightens, and the Lagrange multiplier λ increases. This forces the center to reduce the product

$$(\#\text{ transplanted}) \times (\#\text{ expected deaths}).$$

They can do this in two ways:

- **Raise t^* (fewer transplants).** Since

$$NB(\tilde{x}) = \int \Pi(x, q(x)) p(x|\tilde{x}) dx - \lambda \int P(x, q(x)) p(x|\tilde{x}) dx$$

  increases in $\tilde{x}$, a higher threshold means fewer people qualify for a transplant.

- **Raise q^* (improve post-transplant care).** From

$$q^*(x) = \frac{\rho\,\alpha + (1-\rho)\,x}{(1-\rho)\,\gamma} + \frac{\lambda}{(1-\rho)\,\gamma\,\sigma}\,\phi\!\left(\frac{x+q^*(x)}{\sigma}\right),$$

  a larger λ makes $q^*(x)$ bigger for each x—the center "overspends" on care (relative to the unconstrained level) to reduce mortality.

This completes the proof for proposition 2.

B Stylized model of center behavior with kidney choices

In this section, I formalize the transplant center's incentives and explore how CoP affects decision-making. I present a stylized model where the center observes a noisy signal of patient health and then chooses the transplant eligibility threshold, the kidney type, and the amount of post-transplant care. The center must balance the tradeoffs between profit, patient welfare, and compliance with CoP constraints. Specifically, the center considers the revenue from transplants and post-transplant care, the relative scarcity of good kidneys, and the regulatory penalties from high patient mortality. The model delivers three predictions about the center's response to CoP implementation. First, CoP raises the marginal cost of each transplant by increasing the penalty for poor outcomes, leading centers to reduce transplants. Second, CoP's stricter death constraints increase the marginal benefit of the safer, "expensive" good kidney, resulting in a shift away from bad kidneys. Third, by penalizing poor outcomes, CoP incentivizes centers to increase post-transplant care despite its cost. In subsequent analysis, I model patient mortality in my setting, describe the center's objective function, and characterize the optimal transplant threshold, kidney choice, and post-transplant care. Finally, I provide comparative statics on key parameters and present proofs in the Appendix. Figure B.I illustrates the center's timeline and decision-making.

Stage 1	Stage 2	Stage 3	Stage 4

Observe: signal, $\tilde{x}$
Choice: accept/decline, $A(\tilde{x})$

Choice: kidney, $k(\tilde{x})$

Observe: health, x
Choice: post-transplant care, $q(.)$

**Observe:** death rate, $P(x, k(.), q(.))$ and receive payments

Figure B.I: Timeline of the center behavior

B.1 Setup

Patient health is denoted as x, where $x \sim N(\mu_x, \sigma_x^2)$ [31]. However, when deciding whether to transplant, centers only observe a noisy signal of patient health, $\tilde{x} = x + u$, where $u \sim N(0, \sigma_u^2)$ is independent of x. Thus, $\tilde{x}$ is an unbiased signal for patient health x. Next, the center matches the patient with the good (g) or bad (b) kidney. The good kidney is less risky ($\sigma_g < \sigma_b$). After the transplant, centers observe x and decide on post-transplant care $q(x, k)$. Transplant patients die if the latent variable $y > 0$, where $y = \varepsilon_k - x - q(x, k)$ and $\varepsilon_k \sim N(0, \sigma_k^2)$. ε_k is a normally distributed idiosyncratic shocks with mean 0 and variance σ_k^2. Let the likelihood that a patient with health x, kidney k, and post-transplant care $q(x, k)$ die be $P(x, k, q(x, k)) = 1 - \Phi\left(\frac{q(x,k)+x}{\sigma_k}\right)$, which is decreasing in q and x: more post-transplant care or healthier patient reduces the likelihood of transplant deaths. Similarly, the good kidney reduces mortality due to its lower variance σ_g^2. Conditional on transplant decision, kidney choice and post-transplant care, the center expects $\int_{\tilde{x}} A(\tilde{x}) \int_x P(x, k, q(x, k)) p(x|\tilde{x}) dF(\tilde{x})$ patients to die, where $p(x|\tilde{x})$ is the posterior distribution of x given $\tilde{x}$ and can be derived with Bayes' rule.

I follow Clemens and Gottlieb (2014); Dickstein (2017); Alexander (2020); Shi (2023) and model the center's objective function as a weighted combination of profit and concern for patient utility. The weight placed on profit is ρ and can be interpreted as the center's belief in punishment. In my setting, the center becomes more altruistic and places more weight on patient utility when the likelihood of punishment is low (i.e., low ρ). Medicare pays the center a fixed reimbursement, π for each transplant, and a reimbursement rate α for each unit of post-transplant care, $q(x, k)$. Thus, the center profit is $\pi + \alpha q(x, k)$. A center's concern for patient welfare can be understood as altruism on behalf of the patient or as the center acting to preserve its reputation (Alexander, 2020).

The patient's utility from post-transplant care is concave in $q(x, k)$, reflecting diminishing returns to care. Healthier patients (higher x) derive greater benefits from transplants, but excessive care imposes costs due to coinsurance or opportunity costs on patient's time (Senanayake et al., 2020). The patient also faces a waiting cost of g to receive a good kidney, reflecting the scarcity

---

[31] Patients with higher x are deemed healthier and more suitable for transplant(OPTN, 2023).

of good kidneys. The patient receives zero if centers do not perform a transplant. The center maximizes utility and chooses $A(\tilde{x}), k(\tilde{x}), q(x,k)$ to maximize a weighted average of their profit and the patient's utility from transplant[32]:

$$\max_{A(\tilde{x}),k(\tilde{x})\in\{g,b\},q(x,k)} \int_{\tilde{x}} A(\tilde{x}) \int_{x} \left[\rho \overbrace{[\pi + \alpha q(.)]}^{\text{center profit}} + (1-\rho) \overbrace{\left[xq(.) - \frac{\gamma}{2}q^2(.) - \mathbf{1}_{\{k=g\}}g\right]}^{\text{patient utility}} \right] p(x|\tilde{x})dxdF(\tilde{x})$$

s.t. $\overbrace{\int_{\tilde{x}} A(\tilde{x})}^{\text{"small center discount"}} \overbrace{\int_{x} P(x,k,q(.))p(x|\tilde{x})dx}^{\text{"not too many deaths"}} dF(\tilde{x}) \leq \tau$

$$\tag{12}$$

τ is the CoP limit, and the rest of the terms in the constraint reflect the CoP conditions in Section 2.4. $\int_{x} P(x,k,q(x,k))p(x|\tilde{x})dx$ is equivalent to condition 1: there cannot be too many post-transplant deaths. However, even if there is, the center can still escape CMS flagging if conditions 2 and 3 are unmet. $\int_{\tilde{x}} A(\tilde{x})dF(\tilde{x})$ mimics those conditions and serves as a scaling factor that makes it less likely for small centers to exceed the CoP limit, τ.

Intuitively, the center balances competing incentives. On one hand, it seeks to maximize profit by performing more transplants, using cheaper bad kidneys, and providing reimbursable care. On the other hand, performance concerns and patient welfare impose constraints: (i) transplanting too many patients and using the bad kidney increase the likelihood of exceeding the CoP mortality limit; (ii) patients dislike excessive post-transplant care due to the marginal cost $\gamma > 0$. The center optimally trades off these incentives by adjusting the transplant decision $A(\tilde{x})$, kidney choice $k(\tilde{x})$, and post-transplant care $q(x,k)$. Next, I characterize $A^*(\tilde{x}), k^*(\tilde{x}), q^*(x,k)$ and present the proofs in Appendix.

Proposition 3. *The optimal $q^*(x,k)$ is an implicit solution to the equation 14. $A^*(\tilde{x})$ takes the form*

---

[32]**Note:** The notation $q(x,k)$ is to indicate that post-transplant care is chosen when x and k are observed.

of a cutoff strategy 17 and t^* is the transplant threshold where patients with $\tilde{x} \geq t^*$ will receive transplants and post-transplant care. Conversely, patients with $\tilde{x} < t^*$ will receive no transplants nor post-transplant care. The optimal kidney allocation $k^*(\tilde{x})$ is defined as:

$$
k^*(\tilde{x}) = \begin{cases} g & t^* \leq \tilde{x} < t_g^*, \\ b & \tilde{x} \geq t_g^*, \\ \text{(no transplant)} & \tilde{x} < t^*. \end{cases}
$$

where t_g^*, the good kidney threshold, is the root to equation 16.

Because the center cannot observe a patient's true health x and instead relies on the noisy signal $\tilde{x}$, Proposition 3 implies a negative□sorting allocation rule based on $\tilde{x}$. Specifically, patients whose signals lie in an intermediate range, $\tilde{x} \in [t^*, t_g^*)$, receive the safer (good) kidney, while patients with strong signals, $\tilde{x} \geq t_g^*$, receive the riskier (bad) kidney. The intuition is that for borderline (moderate) signals, the good kidney's lower mortality risk ($\sigma_g < \sigma_b$) provides a significant survival benefit that justifies incurring its waiting cost g. By contrast, for sufficiently high signals $\tilde{x} \geq t_g^*$, that survival benefit diminishes and no longer outweighs g, prompting the center to assign the cheaper (bad) kidney. This tradeoff in expected benefit versus cost naturally yields a cutoff $\tilde{x} = t_g^*$ above which the center switches from good to bad kidneys.

B.2   Comparative statics

In this stylized model, the pre-CoP announcement reflects $\tau \to \infty$, meaning no effective regulatory constraints on the product of transplants and mortality, allowing centers to optimize without restrictions. The post-CoP announcement reflects $\tau < \infty$, introducing binding regulatory constraints. The following result illustrates the comparative statics for the transplant threshold t^*, kidney choice t_g^*, and post-transplant care $q^*(x, k)$ as CMS announces CoP (i.e., τ decreases). I present the proofs in the Appendix.

Proposition 4. *As CMS announces CoP (i.e., τ decreases), the transplant threshold t^* increases*

$\left(\frac{\partial t^*}{\partial \tau} < 0\right)$; *post-transplant care* $q^*(x, k)$ *increases* $\left(\frac{\partial q^*(x,k)}{\partial \tau} < 0\right)$; *the good kidney threshold* t_g^* *increases* $\left(\frac{\partial t_g^*}{\partial \tau} < 0\right)$.

Proposition 4 predicts that as CMS announces CoP, the fraction of patients receiving a transplant decreases. However, this does not imply that enters are actively selecting healthier patients. Instead, the higher threshold t^* makes it more likely for a patient with better true health x to surpass it. Consequently, average health among the smaller set of transplanted patients rises (i.e., $E[x|\tilde{x} > t^*)$ is increasing in t^*). The extent of this rise depends on the informativeness of the noisy signal $\tilde{x}$. When $\tilde{x}$ closely tracks x (i.e., low Var(u)), the stricter threshold effectively excludes less-healthy patients, strongly skewing the transplanted group toward high health. Conversely, if $\tilde{x}$ is weakly informative (i.e., high Var(u)), the higher threshold barely alters the health composition of transplanted patients.

Furthermore, Proposition 4 predicts fewer bad kidney transplants after CMS implements CoP. Using Figure B.II as an example, this decrease is because the center substitutes the bad kidneys with the good kidneys for patients with a strong signal, $\tilde{x} \in [t_g^*, t_g^{*CoP}]$. However, this does not imply more good kidney transplants because patients with intermediate signal, $\tilde{x} \in [t^*, t^{*CoP}]$ will not receive a transplant due to more stringent performance limits. Thus, the effect of CoP on good kidney transplants is ambiguous and depends on the model's parameter values (e.g., high/low waiting cost, g).

(a) Kidney matching when CoP limit, $\tau \to \infty$ (before CoP)

(b) Kidney matching when CoP limit, $\tau < \infty$ (after CoP)

Figure B.II: Kidney matching before CoP v.s. after CoP

Note: Panel A depicts the scenario when the CoP limit is not stringent (e.g., $\tau \to \infty$). Panel B depicts the scenario when the CoP limit is very stringent (e.g., $\tau < \infty$). The model predicts fewer bad kidney transplants because centers substitute the bad kidneys for the good kidneys for patients with a strong signal, $\tilde{x} \in [t_g^*, t_g^{*CoP}]$. On the other hand, patients with intermediate signal, $\tilde{x} \in [t^*, t^{*CoP}]$, do not receive a transplant. Thus, the effect of CoP on good kidney transplants is ambiguous and depends on the parameter value of the model (e.g., high/low waiting cost, g).

B.3 Proofs for Proposition 3 and 4

From equation 12, the center's objective function is

$$\max_{A(\tilde{x}),k\in\{g,b\},q} \int_{\tilde{x}} A(\tilde{x}) \int_{x} \left[\rho \overbrace{[\pi + \alpha q]}^{\text{center profit}} + (1-\rho) \overbrace{\left[xq - \frac{\gamma}{2}q^2 - \mathbf{1}_{\{k=g\}}g \right]}^{\text{patient utility}} \right] p(x|\tilde{x})dxdF(\tilde{x})$$

where the bracketed term is $\Pi(x,k,q)$.

$$\text{s.t. } \int_{\tilde{x}} A(\tilde{x}) \left[\int_{x} P(x,k,q)p(x|\tilde{x})dx \right] dF(\tilde{x}) \leq \tau$$

$$(13)$$

We solve the maximization problem via backwards induction.

B.3.1 Solving for q^*

Let $\lambda \geq 0$ be the Lagrange multiplier on the constraint. Define the Lagrangian:

$$\mathcal{L} = \int_{\tilde{x}} A(\tilde{x}) \int_{x} \left[\Pi(x,k,q) \right] p(x|\tilde{x})dx \, dF(\tilde{x}) \; - \; \lambda \left[\int_{\tilde{x}} A(\tilde{x}) \int_{x} P(x,k,q)p(x|\tilde{x})dxdF(\tilde{x}) - \tau \right].$$

Step 1: If the constraint is slack ($\lambda = 0$). For each x, we differentiate $\Pi(x,k,q)$ with respect to q:

$$\rho\,\alpha + (1-\rho)\big[x - \gamma\,q\big] = 0 \quad \Longrightarrow \quad (1-\rho)\,\gamma\,q = \rho\,\alpha + (1-\rho)\,x.$$

Hence

$$q^{\text{uncon}}(x) = \frac{\rho\,\alpha + (1-\rho)\,x}{(1-\rho)\,\gamma}.$$

Step 2: If the constraint binds ($\lambda > 0$).   For each x, we need

$$\frac{\partial \mathcal{L}}{\partial q} = \int A(\tilde{x}) \frac{\partial \Pi(.)}{\partial q} p(x|\tilde{x}) dx dF(\tilde{x}) - \lambda \int A(\tilde{x}) \frac{\partial P(.)}{\partial q} p(x|\tilde{x}) dF(\tilde{x}) = 0$$

where

$$\frac{\partial}{\partial q} \overbrace{\left\{ \rho(\pi + \alpha\, q) + (1-\rho)\left[x\, q - \tfrac{\gamma}{2} q^2 - \mathbf{1}_{\{k=g\}} g\right] \right\}}^{\Pi(x,k,q)} = \rho\,\alpha + (1-\rho)\left[x - \gamma\, q\right].$$

and

$$\frac{\partial}{\partial q} \overbrace{\left[1 - \Phi\left(\tfrac{x+q}{\sigma_k}\right) \right]}^{P(x,k,q)} = -\phi\left(\tfrac{x+q}{\sigma_k}\right) \frac{1}{\sigma_k},$$

Rearrange for q^*:

$$(1-\rho)\,\gamma\, q^* = \rho\,\alpha + (1-\rho)\, x + \lambda \frac{1}{\sigma_k} \phi\left(\tfrac{x+q^*}{\sigma_k}\right).$$

Thus we have the *implicit* solution:

$$q^*(x,k) = \frac{\rho\,\alpha + (1-\rho)\, x}{(1-\rho)\,\gamma} + \frac{\lambda}{(1-\rho)\,\gamma\,\sigma_k} \phi\left(\tfrac{x+q^*(x,k)}{\sigma_k}\right). \tag{14}$$

If $\lambda = 0$, we revert to the unconstrained optimum. Otherwise, $q^*(x,k)$ exceeds the unconstrained level, reflecting a desire to reduce mortality.

B.3.2   Solving for $k^*(\tilde{x})$

Upon seeing $\tilde{x}$, the center forms a posterior over x, where $p(x|\tilde{x})$ is derived from Bayes' rule, with priors $x \sim N(\mu_x, \sigma_x^2)$ and $u \sim N(0, \sigma_u^2)$. x and u are assumed to be independent. $\Pi(x,k,q^*)$ is the payoff for a transplanted patient of true health x given kidney k as defined in the previous section. Thus, the center chooses k^* at each $\tilde{x}$ such that:

$$k(\tilde{x}) = \arg\max_{k \in \{g,b\}} \overbrace{\int \left[\Pi(x,k,q^*) - \lambda P(x,k,q^*)\right] p(x|\tilde{x})\, dx}^{\widetilde{\Pi}(x,k,q^*)} \tag{15}$$

Next, we define:

$$D(\tilde{x}) = \widetilde{\Pi}(x, g, q^*) - \widetilde{\Pi}(x, b, q^*) \tag{16}$$

As $\tilde{x}$ increases, the posterior shifts to higher x. Since $\widetilde{\Pi}(x, g, q^*)$ and $\widetilde{\Pi}(x, b, q^*)$ differ mainly by the cost g and the difference in survival benefits, then $D(\tilde{x})$ is decreasing in $\tilde{x}$: when $\tilde{x}$ is large, the expected incremental survival benefit of g is smaller, so $D(\tilde{x})$ may become negative, favoring kidney b. Thus, $D(\tilde{x})$ crosses zero exactly once, giving a unique cutoff t_g^*. We have the following cutoff rule:

$$k^*(\tilde{x}) = \begin{cases} g & t \le \tilde{x} < t_g^*, \\ b & \tilde{x} \ge t_g^*, \\ \text{(no transplant)} & \tilde{x} < t^*. \end{cases}$$

B.3.3 Solving for the acceptance rule $A(\tilde{x})$

Define the net benefit function, $NB(\tilde{x})$

$$NB(\tilde{x}) = \int \Pi(x, k, q) p(x|\tilde{x}) dx - \lambda \int P(x, k, q) p(x|\tilde{x}) dx$$

Since the posterior distribution of $p(x|\tilde{x})$ is increasing in $\tilde{x}$, $NB(\tilde{x})$ is a monotonic function of $\tilde{x}$, $A(\tilde{x})$ takes the form of a cutoff strategy:

$$A(\tilde{x}) = \begin{cases} 1 & \text{if } \tilde{x} \ge t^* \\ 0 & \text{if } \tilde{x} < t^* \end{cases} \tag{17}$$

where t^* is such that $NB(t^*) = 0$. This completes the proof for proposition 3.

B.3.4 Comparative Statics: Effect of Decreasing τ

As τ decreases, the regulatory constraint tightens, and the Lagrange multiplier λ increases. This forces the center to reduce the product

$$(\# \text{ transplanted}) \times (\# \text{ expected deaths}).$$

They can do this in two ways:

- **Raise t^* (fewer transplants).** Since

$$NB(\tilde{x}) = \int \Pi(x, q(x))p(x|\tilde{x})dx - \lambda \int P(x, q(x))p(x|\tilde{x})dx$$

  increases in $\tilde{x}$, a higher threshold means fewer people qualify for a transplant.

- **Raise t^*_g (fewer bad kidney transplants).** From

$$D(\tilde{x}) = \widetilde{\Pi}(x, g, q^*) - \widetilde{\Pi}(x, b, q^*)$$

  a larger λ means centers can afford fewer expected deaths than before. This reduces the marginal benefit of the bad kidney and raises t^*_g

- **Raise q^* (improve post-transplant care).** From

$$q^*(x, k) = \frac{\rho\,\alpha + (1 - \rho)\,x}{(1 - \rho)\,\gamma} + \frac{\lambda}{(1 - \rho)\,\gamma\,\sigma_k}\,\phi\!\left(\tfrac{x + q^*(x)}{\sigma_k}\right),$$

  a larger λ makes $q^*(x, k)$ bigger for each x—the center "overspends" on care (relative to the unconstrained level) to reduce mortality.

This completes the proof for proposition 4.

C   Supplementary Figures

Figure C.III: An illustration of the rolling 2.5-year cohort for CoP

Note: The January 2011 submission (black box) consists of transplants from July 1, 2007, to December 31, 2009 (black line). Similarly, the July 2011 submission (red box) contains transplants from January 1, 2008, and June 31, 2010 (red line).

Line		Center 1 Year	National 1 Year
	Adult (Age 18+)		
1	Transplants (n=number)	90	10,781
2	**Percent (%) of Patients Surviving at End of Period**		
3	Observed at this Center	87.78	86.26
4	Expected, based on national experience	89.41	
5	**Deaths During Follow-up Period**		
6	Observed at this center	11	1,392
7	Expected, based on national experience	8.48	1,392
8	Ratio: Observed to Expected (O/E)	1.30	1.00
9	(95% Confidence Interval)	(0.65-2.32)	
10	P-value (2-sided), observed v. expected	0.469	
11	How does this center's survival compare to what is expected for similar patients?	Not Significantly Different (a)	
12	Percent retransplanted	5.5	4.4
13	Follow-up days reported by center (%)	91.7	93.9
14	Maximum Days of Follow-up (n)	365	365

Figure C.IV: An example of a transplant center's CoP report

Note: This table is from Dickinson et al. (2008) and provides an example of a center that did not get flagged for poor performance. The CoP conditions from Section 2.4 can be calculated from this table. For example, Condition 1 is in line 8 (e.g., $O/E = 1.3 < 1.5$); Condition 2 is calculated by taking the difference between lines 6 and 7 (e.g., $O - E = 2.52 < 3$); Condition 3 is in line 10 (e.g., $Pr(O = E) = 0.469 > 0.05$).

Figure C.V: CoP reports and their 2.5-years rolling cohorts

Note: The green bars highlight the 2.5-year rolling cohort for the flagging status of the CoP report in January 2005, July 2005, and January 2006. These reports are built on transplants before the CoP announcement (1st red dotted line). The red bars are CoP reports in July 2006 and January 2007, built on 2.5-year rolling cohorts overlapping with the CoP announcement.

Figure C.VI: Density of actual flagging beliefs in my setting versus simulated beliefs in Gupta (2021)

Note: The blue solid lines are the density of my estimated flagging beliefs ρ_c. The density is similar to a beta distribution with parameter $(\alpha = 1.5, \beta = 5)$ and support $[0, 0.5]$. The red dotted lines are simulated density for Gupta (2021) using a truncated standard normal density with parameter $(\mu = 0.5, \sigma = 0.2)$ and support $[0, 1]$

Figure C.VII: Non-overlapping (solid) and overlapping (dash) patients

Note: This figure highlights my regression subsample in Sections 6 and 6.2. The length of the lines indicates the patient's post-transplant mortality timeline and varies according to the outcome of interest. Patients whose post-transplant mortality timeline do not overlap with CoP announcements have solid lines, and those with dashed lines are excluded from my analysis.

Panel A

Panel B

Figure C.VIII: Impact on post-transplant mortality at different periods

Note: The figure presents the estimated effect on post-transplant mortality at 2-week/6-month/2-year/3-year, obtained using equation 6 with the instrument Z_c and 2003h2 as the reference 6-month window. I use robust standard errors. Error bars indicate 95 percent confidence intervals.

Figure C.IX: Impact on acute kidney rejection at different follow-up periods

Note: The figure presents the estimated effect on the probability of acute kidney rejection at different follow-up periods, obtained using equation 6 with the instrument Z_c and 2003h2 as the reference 6-month window. I use robust standard errors. Error bars indicate 95 percent confidence intervals.

D Supplementary Tables

Table D.I: Death Rates Among Patients Missing Follow-up Care

Time Period	Pre-CoP	Post-Announce	Post-Implement
Dead within 2 weeks	100.0%	100.0%	100.0%
	(N=593)	(N=467)	(N=658)
Dead within 6 months	92.0%	93.3%	94.4%
	(N=3078)	(N=2353)	(N=3207)
Dead within 1 year	94.0%	94.9%	96.0%
	(N=4451)	(N=3500)	(N=4699)

Notes: This table shows the proportion of patients who missed their follow-up appointments due to death. Death rates are calculated as the proportion of patients who died within the specified timeframe among those who did not show up for their scheduled follow-up care.

Table D.II: Tranplanted and discarded kidney characteristics pre and post-CoP

	Transplanted			Discarded		
	Pre-CoP	Post-Ann	Post-Impl	Pre-CoP	Post-Ann	Post-Impl
Age	35.6	36.7	36.7	52.5	53.8	52.1
	(17.3)	(17.1)	(17.0)	(17.0)	(16.5)	(16.1)
Creatinine Levels	1.1	1.1	1.1	1.4	1.5	1.5
	(1.0)	(0.8)	(0.9)	(1.1)	(1.1)	(1.1)
Kidney Risk	0.4	0.4	0.4	0.7	0.8	0.8
	(0.3)	(0.3)	(0.3)	(0.2)	(0.2)	(0.2)
Male	59.6%	60.7%	60.6%	52.2%	53.2%	52.4%
	(49.1)	(48.8)	(48.9)	(50.0)	(49.9)	(49.9)
White	72.4%	68.5%	67.6%	72.2%	68.9%	68.2%
	(44.7)	(46.4)	(46.8)	(44.8)	(46.3)	(46.6)
Death - Stroke	37.8%	35.9%	32.2%	65.9%	64.8%	56.3%
	(48.5)	(48.0)	(46.7)	(47.4)	(47.8)	(49.6)
Death - Head Trauma	47.2%	44.9%	39.4%	19.8%	17.6%	17.5%
	(49.9)	(49.7)	(48.9)	(39.9)	(38.1)	(38.0)
Hypertension	19.6%	24.1%	25.7%	52.7%	61.1%	61.2%
	(39.7)	(42.8)	(43.7)	(49.9)	(48.7)	(48.7)
Total Offers	95.0	69.9	176.3	796.4	545.0	1334.4
	(505.2)	(300.9)	(701.4)	(2352.7)	(1084.5)	(2430.6)
Observations	37975	33846	58325	5750	6634	12968

Notes: This table presents means and standard deviations (in parentheses) for kidney donor characteristics. The sample is split between transplanted and discarded kidneys before and after the CoP announcement and implementation. If a pair of kidneys were recovered, but only one was transplanted, they would each count as an observation in the transplanted and discarded columns.

Table D.III: Tranplant patient characteristics pre and post-CoP

	Pre-CoP	Post-CoP	
		Announcement	Implementation
Age	47.9	49.4	50.8
	(14.5)	(15.3)	(15.3)
White	51.7%	48.8%	45.7%
	(50.0)	(50.0)	(49.8)
Years on WL	2.2	2.3	2.7
	(1.9)	(2.0)	(2.2)
Completed Univ.	14.2%	16.0%	19.1%
	(34.9)	(36.6)	(39.3)
Medicare	60.5%	61.0%	65.1%
	(48.9)	(48.8)	(47.7)
Diabetic	31.2%	33.8%	36.3%
	(46.4)	(47.3)	(48.1)
On Dialysis	55.9%	75.9%	75.7%
	(49.7)	(42.8)	(42.9)
Total Offers	55.9	69.5	133.3
	(72.3)	(103.0)	(209.7)
Ecpected Post-TX Survival	31.2	35.2	39.3
	(29.7)	(31.0)	(32.4)
Observations	36446	32575	55583

Notes: This table presents means and standard deviations (in parentheses) for transplant patient characteristics. The three columns cover transplants performed over the pre-CoP (January 2001 - February 2005), post-CoP announcement (February 2005 - July 2007), and post-CoP implementation (July 2007 - December 2012) periods.

Table D.IV: Impact on different post-transplant timeline mortality

	Post-transplant $\leq$ 1-year			Post-transplant $>$ 1-year	
	(1)	(2)	(3)	(4)	(5)
	2-weeks	6-months	1-year	2-years	3-years
Post-Announce	-0.01057***	-0.02696***	-0.02777***	-0.00937	0.01012
	(0.00296)	(0.00480)	(0.00582)	(0.00768)	(0.01111)
Post-Implement	-0.01523***	-0.03123***	-0.02212***	0.00217	0.02823**
	(0.00266)	(0.00431)	(0.00524)	(0.00708)	(0.01058)
Y mean	0.02801	0.07573	0.11036	0.17144	0.23285
F-statistic	15805.65184	15197.02759	14713.68470	13759.31457	12762.85322
Fixed Effects	Center, 6-months	Center, 6-months	Center, 6-months	Center, 6-months	Center, 6-months
Observations	113803	109569	105264	97206	89312

Note: This table relates to the analysis in Section 6.1. It presents the estimated effect on the probability of deaths at different post-transplant timelines, obtained by jointly estimating equations 4, 5. Each column uses the subsample of patients whose post-transplant mortality timeline does not overlap with the CoP announcement described in Section 5.3. I use robust standard errors. *$p < 0.1$, **$p < 0.05$, *** $p < 0.01$

Table D.V: Impact on the prescription of maintenance immunosuppressants

	(1) 2-weeks	(2) 6-months	(3) 1-year	(4) 2-years
Post-Announce	0.00282	0.02110***	-0.00179	0.03767***
	(0.00258)	(0.00401)	(0.00308)	(0.00677)
Post-Implement	0.01049***	0.05341***	-0.00613*	0.01145
	(0.00199)	(0.00407)	(0.00300)	(0.00667)
Y mean	0.97251	0.66734	0.79945	0.69618
F-statistic	15747.43382	14059.37189	13392.63835	10959.45778
Fixed Effects	Center, 6-months	Center, 6-months	Center, 6-months	Center, 6-months
Observations	114535	102717	95384	83002

Note: This table relates to the analysis in Section 6.3.1. It presents the estimated effect on the probability of prescribing maintenance immunosuppressants at different follow-up timelines, obtained by jointly estimating equations 4, 5. Each column uses the subsample of patients whose post-transplant mortality timeline does not overlap with the CoP announcement described in Section 5.3. I use robust standard errors. $*p < 0.1$, $**p < 0.05$, $***p < 0.01$.

Table D.VI: Impact on the rate of acute kidney rejection

	(1)	(2)	(3)	(4)
	2-weeks	6-months	1-year	2-years
Post-Announce	-0.00756**	-0.00401	0.00878	0.01676**
	(0.00259)	(0.00488)	(0.00456)	(0.00539)
Post-Implement	-0.00605**	-0.00248	0.00434	0.00733
	(0.00234)	(0.00483)	(0.00444)	(0.00516)
Y mean	0.02981	0.06683	0.03720	0.03098
F-statistic	16396.47443	14157.17526	13533.28614	11654.98563
Fixed Effects	Center, 6-months	Center, 6-months	Center, 6-months	Center, 6-months
Observations	114885	95194	88568	77137

Note: This table relates to the analysis in Section 6.3.2. It presents the estimated effect on the probability of acute kidney rejection episodes being reported at different follow-up timelines, obtained by jointly estimating equations 4, 5. Each column uses the subsample of patients whose post-transplant mortality timeline does not overlap with the CoP announcement described in Section 5.3. I use robust standard errors. *$p < 0.1$, **$p < 0.05$, ***$p < 0.01$.

Table D.VII: Impact on the rate of CMV testing

	(1) 2-weeks	(2) 1-year	(3) 2-years
Post-Announce	-0.01564***	0.04198***	0.06242***
	(0.00377)	(0.00661)	(0.00779)
Post-Implement	0.00745*	0.03114***	0.01361*
	(0.00290)	(0.00588)	(0.00653)
Y mean	0.95981	0.28389	0.31329
F-statistic	15809.71469	13392.63835	10959.45778
Fixed Effects	Center, 6-months	Center, 6-months	Center, 6-months
Observations	114885	95384	83002

Note: This table examines the proposed detection channel in section 6.3.2. It presents the estimated effect on the probability of centers performing a CMV test at different follow-up timelines, obtained by jointly estimating equations 4, 5. Each column uses the subsample of patients whose post-transplant mortality timeline does not overlap with the CoP announcement described in Section 5.3. I use robust standard errors. $*p < 0.1$, $**p < 0.05$, $***p < 0.01$.

Table D.VIII: Impact on viral infection deaths

	(1) 2-weeks	(2) 6-months	(3) 1-year	(4) 2-years
Post-Announce	-0.00449*	-0.00995***	-0.01094***	-0.01213**
	(0.00175)	(0.00258)	(0.00299)	(0.00377)
Post-Implement	-0.00721***	-0.01208***	-0.01458***	-0.01683***
	(0.00155)	(0.00230)	(0.00268)	(0.00346)
Y mean	0.00885	0.01812	0.02193	0.02662
F-statistic	15805.46382	15197.31618	14713.95975	13759.58801
Fixed Effects	Center, 6-months	Center, 6-months	Center, 6-months	Center, 6-months
Observations	113804	109570	105265	97207

Note: This table relates to the analysis in Section 6.3.2. It presents the estimated effect on the probability of death by viral infection at different post-transplant timelines, obtained by jointly estimating equations 4 and 5. Each column uses the subsample of patients whose post-transplant mortality timeline does not overlap with the CoP announcement described in Section 5.3. I use robust standard errors. $*p < 0.1$, $**p < 0.05$, $*** p < 0.01$

Table D.IX: Impact on acceptable donor criteria (i)

	(1) Min. Age	(2) Max. Age	(3) HLA Mismatch	(4) Creatinine
Post-Announce	0.03917	-0.73965*	0.00707	-0.82138
	(0.04781)	(0.32938)	(0.01299)	(1.34205)
Post-Implement	0.04438	0.78721	-0.01107	2.51965
	(0.10207)	(0.58262)	(0.01816)	(2.41131)
Y mean	1.22524	78.86188	5.94687	17.45362
Fixed Effects	Patient, Quarters	Patient, Quarters	Patient, Quarters	Patient, Quarters
Observations	26890	26890	26350	26890

Note: This table relates to the analysis in section 7.1.1. It presents the estimated effect on centers setting more stringent donor criteria, obtained by estimating equation 8. Each column represents a different modifiable donor criterion. I use robust standard errors. *$p < 0.1$, **$p < 0.05$, *** $p < 0.01$

Table D.X: Impact on acceptable donor criteria (ii)

	(1) Hypertension	(2) Cold Ischemic Time	(3) Warm Ischemic Time	(4) Expanded Criteria
Post-Announce	0.00039	1.23367	-0.09437	0.00127
	(0.00038)	(2.22015)	(1.06507)	(0.01270)
Post-Implement	0.00099	10.63076**	3.25256	-0.03059
	(0.00163)	(3.52796)	(1.87777)	(0.01971)
Y mean	0.99821	58.82800	66.02855	0.34128
Fixed Effects	Patient, Quarters	Patient, Quarters	Patient, Quarters	Patient, Quarters
Observations	26890	26890	23220	26890

Note: This table relates to the analysis in section 7.1.1. It presents the estimated effect on centers setting more stringent donor criteria, obtained by estimating equation 8. Each column represents a different modifiable donor criterion. I use robust standard errors. *$p < 0.1$, **$p < 0.05$, *** $p < 0.01$

Table D.XI: Impact on acceptance decision across subgroups (i)

	(1) White	(2) Diabetic	(3) Uni.	(4) Medicare	(5) On dialysis
Post-Ann (Tri)	0.00304	-0.00043	0.00399	0.00442	0.00794
	(0.00437)	(0.00433)	(0.00492)	(0.00373)	(0.00432)
Post-Imp (Tri)	-0.00121	-0.00098	0.00192	0.00737	0.00507
	(0.00536)	(0.00393)	(0.00380)	(0.00507)	(0.00509)
Y mean	0.05689	0.05689	0.05689	0.05689	0.05689
Fixed Effects	Center, 6-months	Center, 6-months	Center, 6-months	Center, 6-months	Center, 6-months
Observations	880506	880506	880506	880506	880506

Note: This table relates to the analysis in section 6.2.1. It presents the estimated effect on the center's acceptance decision across different subgroups, obtained from triple differences regression interacted with different patient characteristics. I use robust standard errors. *$p < 0.1$, **$p < 0.05$, *** $p < 0.01$

Table D.XII: Impact on acceptance decision across subgroups (ii)

	(1) White	(2) Diabetic	(3) Hypertension	(4) Death-Stroke	(5) Death-Head Trauma
Post-Ann (Tri)	0.00297	0.00683	0.00677	0.00045	-0.00105
	(0.00329)	(0.00437)	(0.00457)	(0.00324)	(0.00376)
Post-Imp (Tri)	-0.00236	0.00701	0.00350	-0.00021	-0.00284
	(0.00359)	(0.00422)	(0.00405)	(0.00330)	(0.00381)
Y mean	0.05689	0.05689	0.05689	0.05689	0.05689
Fixed Effects	Center, 6-months	Center, 6-months	Center, 6-months	Center, 6-months	Center, 6-months
Observations	880506	880506	880506	880506	880506

Note: This table relates to the analysis in section 6.2.1. It presents the estimated effect on the center's acceptance decision across different subgroups, obtained from triple differences regression interacted with different kidney characteristics. I use robust standard errors. *$p < 0.1$, **$p < 0.05$, *** $p < 0.01$

Table D.XIII: Impact on transplanted patient health

	(1) EPTS	(2) Creatinine
Post-Announce	-0.29275	-0.06437
	(0.24930)	(0.05155)
Post-Implement	-1.01252***	0.04067
	(0.22771)	(0.04788)
Y mean	36.42286	8.10584
F-statistic	14845.59951	14712.22787
Fixed Effects	Center, 6-months	Center, 6-months
Observations	107717	105265

Note: This table relates to the analysis in section 6.2.1. It presents the estimated effect on transplanted patient charac-teristics, obtained by estimating equation 5. I use robust standard errors. *$p < 0.1$, **$p < 0.05$, *** $p < 0.01$

Table D.XIV: Impact on admitted patient characteristics (i)

	(1) Age	(2) White	(3) No education	(4) Working	(5) Medicare
Post-Announce	-0.12504	-0.00304	-0.00187	-0.00836***	0.01617***
	(0.09173)	(0.00290)	(0.00220)	(0.00237)	(0.00317)
Post-Implement	-0.12850	-0.00152	-0.02350***	0.00202	-0.00072
	(0.07889)	(0.00249)	(0.00182)	(0.00207)	(0.00274)
Y mean	49.64180	0.47940	0.12864	0.19979	0.49139
Fixed Effects	Centers, 6-months	Centers, 6-months	Centers, 6-months	Centers, 6-months	Centers, 6-months
Observations	364083	364083	364083	364083	364083

Note: This table relates to the analysis in section 7.1.2. It presents the estimated effect on admitted patient characteristics, obtained by estimating equation 5. I use robust standard errors. *$p < 0.1$, **$p < 0.05$, *** $p < 0.01$

Table D.XV: Impact on admitted patient characteristics (ii)

	(1) BMI	(2) Diabetic	(3) On dialysis	(4) Blood type O
Post-Announce	-0.14220***	-0.00001	-0.00246	0.13240
	(0.03880)	(0.00318)	(0.00258)	(0.32871)
Post-Implement	-0.15560***	0.00001	0.00029	0.14281
	(0.03303)	(0.00273)	(0.00221)	(0.28093)
Y mean	27.88551	0.40196	0.76968	48.53371
Fixed Effects	Centers, 6-months	Centers, 6-months	Centers, 6-months	Centers, 6-months
Observations	356297	364083	364083	364083

Note: This table relates to the analysis in section 7.1.2. It presents the estimated effect on admitted patient characteristics, obtained by estimating equation 5. I use robust standard errors. *$p < 0.1$, **$p < 0.05$, *** $p < 0.01$

Table D.XVI: Impact on kidney discard

	Kidney Discards		No. of Patients Offered	
	(1)	(2)	(3)	(4)
	Baseline	Risky Kidney	Baseline	Risky Kidney
Post-Announce	0.00720	-0.00780*	17.97013***	4.07020
	(0.00425)	(0.00329)	(4.85904)	(4.53587)
Post-Implement	-0.00513	-0.00867**	-61.44860***	-23.73487***
	(0.00350)	(0.00289)	(5.42300)	(4.91193)
Post-Announce (Tri)		0.03596***		35.81557***
		(0.00959)		(9.57540)
Post-Implement (Tri)		0.00522		-95.73517***
		(0.00791)		(11.08671)
Y mean	0.15538	0.15538	270.16646	270.16646
Fixed Effects	DSA, 6-months	DSA, 6-months	DSA, 6-months	DSA, 6-months
Observations	107444	107444	107444	107444

Note: This table relates to the analysis in section **??**. It presents the estimated effect on kidney discard, obtained by estimating equation 7. I use robust standard errors. $*p < 0.1$, $**p < 0.05$, $*** p < 0.01$

Table D.XVII: Full patient sample

	Post-Transplant Death	CMV Testing	Immunosuppression
2-weeks after transplant			
Post-Ann	-0.004*	-0.013***	-0.040***
	(0.002)	(0.003)	(0.003)
Post-Imp	-0.007***	0.033***	-0.047***
	(0.002)	(0.002)	(0.003)
6-months after transplant			
Post-Ann	-0.011***	0.022***	0.005**
	(0.003)	(0.004)	(0.002)
Post-Imp	-0.014***	0.036***	0.013***
	(0.003)	(0.004)	(0.002)
1-year after transplant			
Post-Ann	-0.011***	0.031***	0.046***
	(0.004)	(0.004)	(0.004)
Post-Imp	-0.010***	0.017***	0.062***
	(0.003)	(0.004)	(0.003)

Notes: This table relates to the analysis in section 7.2. It presents the estimated effect on post-transplant death, CMV testing, and immunosuppressant prescription, obtained by estimating equation 5 with the full patient sample. I use robust standard errors. $*p < 0.1$, $**p < 0.05$, $*** p < 0.01$

Table D.XVIII: Transplant centers have perfect foresight

	Post-Transplant Death	CMV Testing	Immunosuppression
2-weeks after transplant			
Post-Ann	-0.019**	0.006	0.041***
	(0.007)	(0.010)	(0.010)
Post-Imp	-0.027***	0.058***	0.010
	(0.006)	(0.007)	(0.009)
6-months after transplant			
Post-Ann	-0.051***	0.074***	0.016**
	(0.012)	(0.013)	(0.007)
Post-Imp	-0.051***	0.059***	0.009
	(0.011)	(0.012)	(0.006)
1-year after transplant			
Post-Ann	-0.048***	0.043***	-0.094***
	(0.014)	(0.015)	(0.014)
Post-Imp	-0.026**	0.018	-0.093***
	(0.013)	(0.012)	(0.014)

Notes: This table relates to the analysis in section 7.2. It presents the estimated effect on post-transplant death, CMV testing, and immunosuppressant prescription, obtained by estimating equation 5, but replacing the ρ_c with the flagged status of the center in 2007h2 when Medicare implemented CoP. I use robust standard errors. *$p < 0.1$, **$p < 0.05$, *** $p < 0.01$

Table D.XIX: Transplant centers have time-varying flagging beliefs

	Post-Transplant Death	CMV Testing	Immunosuppression
2-weeks after transplant			
Post-Ann	-0.000	-0.005***	-0.004*
	(0.001)	(0.002)	(0.002)
Post-Imp	-0.001	0.016***	-0.012***
	(0.001)	(0.001)	(0.002)
6-months after transplant			
Post-Ann	-0.004**	0.013***	0.002
	(0.002)	(0.002)	(0.001)
Post-Imp	-0.003*	0.001	0.000
	(0.002)	(0.002)	(0.001)
1-year after transplant			
Post-Ann	-0.005**	0.013***	0.013***
	(0.002)	(0.003)	(0.002)
Post-Imp	-0.002	0.002	0.030***
	(0.002)	(0.002)	(0.002)

Notes: This table relates to the analysis in section 7.2 . It presents the estimated effect on post-transplant death, CMV testing, and immunosuppressant prescription, obtained by estimating equation 5, but replacing the ρ_c with time-varying flagging beliefs. I use robust standard errors. $*p < 0.1$, $**p < 0.05$, $*** p < 0.01$